Document1
CURRICULUM VITAE
NAME:
Lawrence S. Phillips, M.D.
EMORY OFFICE ADDRESS:
Division of Endocrinology, Emory University
Woodruff Memorial Research Building, Room 1027
101 Woodruff Circle
Atlanta, GA 30322
Phone (404) 727-1392; Fax (404) 727-1300
E-mail: medlsp@emory.edu
VA OFFICE ADDRESS:
Atlanta VA Medical Center, 11C-124
1670 Clairmont Road
Decatur, GA 30033-9819
Atlanta, GA 30322
Phone (404) 728-7608; Fax (404) 417-2944
E-mail: medlsp@emory.edu
HOME ADDRESS:
1799 Castleway Lane, Atlanta, GA 30345
DATE AND PLACE OF BIRTH:
September 16, 1941 - Washington, DC, USA
EDUCATION:
1963
B.A.
Swarthmore College, Swarthmore, Pennsylvania
1967
M.D.
Harvard Medical School, Boston, Massachusetts
EMPLOYMENT AND TRAINING:
1967-1969
Internship and Residency; Rush-Presbyterian-St. Luke's Hospital, Chicago, Illinois
1969-1971
Center for Disease Control; Lab Program (USPHS) Atlanta, Georgia
1969-1971
Staff Associate, Grady Memorial Hospital, Atlanta, Georgia
1970-1971
Instructor in Medicine, Emory University School of Medicine, Atlanta, Georgia
1971-1974
Fellow in Metabolism, Washington University School of Medicine, St. Louis, Missouri
1972-1974
Assistant Physician, Barnes Hospital, St. Louis, Missouri
1974-1979
Assistant Professor of Medicine, Department of Medicine; Member, Center for
Endocrinology, Metabolism and Nutrition; Northwestern University Medical School,
Chicago, Illinois
1974-1983
Adjunct Attending Physician, then Associate Attending Physician, then Attending
Physician. Northwestern Memorial Hospital, Chicago, Illinois
1979-1983
Associate Professor of Medicine, Department of Medicine; Member, Center for
Endocrinology, Metabolism and Nutrition, Northwestern University Medical School,
1
Document1
Chicago, Illinois
1983-
Professor of Medicine; Associate Professor of Physiology; Department of Medicine,
Emory University School of Medicine; Member, Emory Clinic
1983-1999
Director, Division of Endocrinology and Metabolism, Department of Medicine, Emory
University School of Medicine
1985-
Partner, Emory Clinic
2002-2005
Program Director, General Clinical Research Center, Emory University
2006-
Medical Director, Clinical Studies Center, Atlanta VA Medical Center
2010-
Adjunct Faculty; Hubert Department of Global Health; Rollins School of Public Health;
Emory University
HONORS:
B.A. with Honors, 1963
Sigma Xi, 1963
Elliot P. Joslin Research and Development Award, American Diabetes Association, 1977
Listed in The Best Doctors in America, 1998Dean’s Clinical Investigator Award, Emory University School of Medicine, 2001
Placed above 95th percentile of distribution of extramural research grants over the last 25 years by NIH, 2004
Outstanding Clinical Research Citation, Department of Medicine, Emory University School of Medicine, 2008
MilliPub Club, Emory University School of Medicine, 2009, 2013 (“classic” publications – over 1000 citations)
BOARD CERTIFICATION
American Board of Internal Medicine, 6/72 # 040131
Subspeciality Boards in Endocrinology and Metabolism, 10/73 # 040131
GEORGIA MEDICAL LICENSE # 025016 (expires 09/30/15)
EDITORIAL BOARDS:
Endocrinology (1979-1983)
Core Journals in Clinical Endocrinology (1982-1988)
Diabetes (1991-1994)
American Journal of Medical Science (1992-1997)
Reviewer: Diabetes, Journal of Clinical Endocrinology and Metabolism, Journal of Clinical Investigation,
Metabolism, Endocrinology
SCIENTIFIC ADVISORY FUNCTIONS:
Human Growth Foundation, Research Grants Review Committee (1977-1979)
American Diabetes Association, Committee on Statistics (1977-1979)
American Diabetes Association, Ad Hoc Committee on Gestational Diabetes (1979-1980)
American Diabetes Association, Committee on Research (1983-1986)
American Diabetes Association, Georgia Affiliate: Board of Directors, 1984 -1991;
Research Committee - 1984 (Chairman, 1986 - 1990)
American Diabetes Association, Clinical Education Program (1984-1985)
Georgia Department of Human Resources, Diabetes Advisory Board (1985- )
2
Document1
American College of Physicians, MKSAP VII Course Director, Atlanta, GA (5/86)
NIH DDK-B Special Grants Review Committee for Diabetes, Endocrinology, and
Metabolism (1987 - 1992)
Roerig-Pfizer, Academic Advisory Committee (1989 -1991)
Pre-reviewer, ACGME, Subspecialty programs in Endocrinology, Diabetes, and Metabolism (1997- )
MEMBERSHIPS IN SCIENTIFIC SOCIETIES:
Endocrine Society (Education Committee 1988-91)
American Diabetes Association
American Federation of Clinical Research
Chicago Endocrine Club (President 1978-79)
Central Society for Clinical Research
Southern Society for Clinical Investigation
American Association for the Advancement of Science
American Society for Clinical Investigation
MEDICAL CENTER COMMITTEES:
Northwestern University Institutional Review Board (1978-80),
Panel Chairman (1979-80)
Northwestern Memorial Hospital Research Committee (1980-83)
Northwestern University Computer Funds Allocation Committee (1982-83)
Northwestern University Medical School New Building Committee (1982-83)
Northwestern University M.D. - Ph.D. Applicant Interview Committee (1982-83)
Emory University School of Medicine Tenure and Promotions Committee (1983-88)
Emory University School of Medicine Long-Range Planning Committee (1985-)
Emory University School of Medicine Clinical Research Facility Director Search
Committee (1984-85)
Emory University School of Medicine Liaison Committee for Medical Education Research
Subcommittee (1984-85)
Emory University School of Medicine/VA ACOS/Research Search Committee Chairman
(1987)
Emory University School of Medicine Pathophysiology Curriculum Committee (1992)
Emory University School of Medicine Faculty Development Workshop Committee Chairman (1994)
Emory Healthcare Strategic Planning Committee - Chronic Diseases (1997)
Emory University School of Medicine Education Strategic Planning Committee, Co-Chair, Curriculum
Committee III (1998)
Emory University School of Medicine Research Advisory Committee (2002-2005)
Emory University School of Medicine Strategic Planning Committee (2002-2005)
Atlanta VA Medical Center Research and Development Committee (2007-)
Veterans Integrated Service Network (VISN) 7 Information Assurance Committee (2008-)
3
Document1
COMPETITIVE RESEARCH AWARDS (largely Principal Investigator or Program Director)
Somatomedin and Growth in Diabetes Mellitus and
Nutritional Deprivation (P.I.)
Chicago Diabetes Association
(1975-76)
Regulation of Somatomedin Production in the Livers of
Diabetic and Malnourished Rats (P.I.)
Chicago Diabetes Association
(1976-77)
Research and Development Award (P.I.)
American Diabetes Association
(1976-77)
Research and Development Award (P.I.)
American Diabetes Association
(1977-78)
Role of Insulin and Nutrition in Regulation of
Somatomedin and Growth (P.I.)
American Diabetes Association
(1976-77)
Metabolic Fuels, Diabetes and Somatomedin Activity
(P.I.)
National Institutes of Health
#R01 AM21483
(1978-81)
Metabolic Fuels, Diabetes and Somatomedin Activity
(P.I.)
#RO1 AM21483
(1981-86)
[#R01 AM33475 for (1983-86)]
Nutritional Studies of Somatomedin Inhibitors (P.I.)
Abbott Laboratories
(1984-91)
Training Program in Endocrinology, Metabolism, and
Diabetes (P.I.)
National Institutes of Health
T32 #DK07298
(1985-90)
Uremic Somatomedin Inhibitor (P.I.)
National Institutes of Health
#R01 DK34785
(1986-90)
Metabolic Fuels, Diabetes and Somatomedin Activity (P.I.)
#R01 DK33475
Molecular Regulation of Hepatic IGF-1 in Diabetes (P.I.)
National Institutes of Health
#R03 DK41187
(1988-91)
Training Program in Endocrinology, Metabolism, and
Diabetes (P.I.)
National Institutes of Health
T32 #DK07298
(1990-95)
Transcriptional Regulation of IGF-1 and IGF Binding
Protein-1 (BP-1) in Diabetes Mellitus (P.I.)
American Diabetes Association
(1992-93)
Metabolic Fuels, Diabetes and IGF Activity (P.I.)
National Institutes of Health
#R01 DK33475
(1992-96)
Improving Primary Care of African-Americans with
NIDDM (P.I.)
National Institutes of Health
#R01 DK48124
(1994-98)
Training Program in Endocrinology, Metabolism, and
Diabetes (P.I.)
National Institutes of Health
T32 #DK07298
(1995-2000)
(1986-91)
4
Document1
Metabolic Fuels, Diabetes and IGF Activity (P.I.)
National Institutes of Health
#R01 DK33475
(1997-2000)
Improving Primary Care of African-Americans with
NIDDM (P.I.)
AHCPR/NIDDK
#R01 HS09722
Training Program in Endocrinology, Metabolism, and
Diabetes (Program Director through 2002)
National Institutes of Health
T32 #DK07298
(2000-2005)
Vanguard Clinical Center for Clinical Trial and Observational
Study of Women’s Health Initiative – East/West Pool 1 (P.I.)
NIH/NHLBI
#N01-WH-3-2111
General Clinical Research Center
(Program Director 2002-2005)
National Institutes of Health
#RR 00039
(1999-2004)
Depression-Diabetes Mechanisms: Urban AfricanAmericans (Co-P.I.)
National Institutes of Health
#R01 MH63302
(2003-2008)
Screening for IGT: Glucose Challenge vs. Predictive
Model (P.I.)
National Institutes of Health
#R18 DK066204
(2004-2009)
Cardiovascular risk identification and prevention
in patients with early abnormalities in glucose tolerance
(Mentor)
National Institutes of Health
#K12 RR 017643
(2004-2009)
The Emory-Morehouse Partnership to Reduce CV Disparities
(Co-I.)
National Institutes of Health
#U01 HL79156
(2004-2009)
Field Centers for the Women’s Health Initiative Extension
(P.I.)
NIH/NHLBI
#N01-WH-3-2111
(2005-2010)
Plasma Proteome Profiling in Insulin Resistance
(Co-I.)
NIH/NIDDK
# R21 DK075745
(2007-2009)
Biomarker Assessment of Metabolic and Vascular Risk
- “Predictive Health” (P.I.)
Robert W. Woodruff Health Sciences Center
Fund
(2005-2009)
Accuracy of Initial Diagnosis of Diabetes in VHA (P.I.)
Dept of Veterans Affairs, HSR&D Service
# SHP 08-144
(2008)
Screening for Prediabetes and Early Diabetes in Primary Care
(P.I.)
Dept of Veterans Affairs, HSR&D Service
IIR 07-138-3
(2008-2012)
Free fatty acid-induced hypertension and endothelial
dysfunction in obese subjects (Umpierrez)
(Co-I.)
American Diabetes Association
# 0000002574
(2008-2010)
Melatonin and the metabolic syndrome (Kutner)
(Co-I.)
NIH/NCCAM
# R21 AT004220
Prevention of Cystic Fibrosis Diabetes (Stecenko)
(Co-P.I.)
Food and Drug Administration
# FDA RO1FD003527 (2009-2013)
A culturally tailored lifestyle intervention (Narayan)
NIH/NIDDK
(1998-2004)
(1993-2005)
(2008-2011)
5
Document1
to prevent diabetes in South Asians: a pilot study
(Co-I)
# R34 DK081723
(2009-2012)
DiaSys: Computerized decision support (Mohan)
to improve diabetes management in primary care
(Co-I)
Emory Healthcare Innovation Program
(2012)
Practical two-step screening for CFRD and prediabetes
(P.I.)
Cystic Fibrosis Foundation (CFF)
(2012-2015)
5-year comparative effectiveness study: (Nathan)
The Glycemia Reduction Approaches for Diabetes:
A Comparative Effectiveness Study (Co-I., site P.I.)
(Co-I; Site P.I.)
NIH/NIDDK
(2013-2020)
Vitamin D for Type 2 Diabetes (D2d trial) (Pittas)
(Co-I., site P.I.)
NIH/NIDDK
(2013-2018)
Reach, outcomes and system impacts of the VA's
national weight loss program, MOVE
(PI)
NIH/NIDDK
R21DK099716
(2014-2016)
6
Document1
CLINICAL TRIALS
Genentech Protocol #M0431G, Multicenter, double-blind,
Genentech, Inc.
randomized study of the safety and efficacy of somatropin
(rDNA origin) for injection to improve physical and
psychosocial well-being in growth hormone deficient adults (P.I.)
(1993-95)
Bristol-Myers Squibb, Inc., Protocol # 138-001. Dose
Response Study of Various Dose Levels of Metformin
Hydrochloride Compared to Placebo in Patients with
Non-insulin Dependent Diabetes Mellitus (P.I.)
Bristol-Myers Squibb
Genentech, Inc., Protocol F0615g. A Randomized, placebocontrolled phase II dose ranging study of the safety and
efficacy of rhIGF-I administered twice daily for the treatment
of Type II diabetes mellitus. (P.I.)
Genentech, Inc.
Genentech, Inc., Protocol F0625g. A Randomized, placebocontrolled phase II dose ranging study of the safety and
efficacy of rhIGF-I administered once daily for the treatment
of Type II diabetes mellitus. (P.I.)
Genentech, Inc.
Genentech, Inc., Protocol F0685g. Phase II study of
pharmacokinetic/pharmacodynamic effects of rhIGF-1. (P.I.)
Genentech, Inc.
Parke-Davis Protocol 991-093, A 48 week, active-controlled,
open-label extension of a double-blind, multicenter
study of CI-991 and CI-991/Sulfonylurea combination in
patients with non-insulin dependent diabetes mellitus
Parke-Davis
Takeda America, Inc. Protocol # AO-128/PNFP-004. A
Randomized, Double-Blind, Placebo-Controlled, Six Month
Safety and Efficacy Trial of Voglibose.
Takeda America, Inc.
SmithKline Beecham Protocol 024. A 26-week
Randomized, Double-Blind, Multicenter, Placebo-Controlled
Study to Evaluate the Safety, Efficacy, and Tolerability of
BRL 49653C Therapy.
SmithKline Beecham Pharmaceuticals
(1997)
Novartis, Study No. DJN B302-E-00. A Double-Blind,
Parellel-Group, Study to Prospectively Evaluate the Safety,
Efficacy and Tolerability of Three Fixed Dose Levels of
SDZ DJN 608 and Placebo in Subjects with Non-InsulinDependant Diabetes Mellitus Previously Treated with Diet
Alone
Novartis Pharmaceuticals Corporation
(1997)
Eli Lilly Protocol HypoCCS-1, The hypopituitary
control and complications trial
Eli Lilly
SmithKline Beecham Pharmaceuticals, Protocol #105
An open-labeled extension study to assess the long-term
safety, tolerability and efficacy of BRL 49653C when
administered as monotherapy, once daily, to patients
with non-insulin dependent diabetes mellitus (NIDDM)
SmithKline Beecham Pharmaceuticals
(8/97 - 10/98)
(1995-1996)
(1994-1995)
(1994-1995)
(3/96 - 10/96)
(7/96 - 8/97)
(1997)
(2/97 - present)
7
Document1
Novartis Protocol B-356-E-00, A multicenter, doubleblind, randomized, parallel-group study to compare the
efficacy, tolerability and safety of SDZ DJN 608
monotherapy, troglitazone monotherapy and a
combination of SDZ DJN 608 and troglitazone to
placebo in subjects with non-insulin dependent diabetes
mellitus inadequately controlled on diet alone.
Novartis Pharmaceuticals Corporation
(3/98 - present)
Bayer Protocol No. CTD-98-05, Microalbustix reagent
strip testing
Bayer Pharmaceuticals
Sensus Drug Development Corporation Protocol
No. SEN 3614, A phase III double-blind, placebocontrolled study of B2036-PEG in the treatment of
acromegaly
Sensus Drug Development Corporation
(6/98 - 1/99)
Sensus Drug Development Corporation Protocol
No. SEN 3614, An open-label extension study of
B2036-PEG in the treatment of acromegaly
Sensus Drug Development Corporation
(10/98 - 10/01)
Eli Lilly Protocol HypoCCS-1 (B9R-MC-GDEE-1),
The Hypopituitary control and complications study,
BMD addendum
Eli Lilly
Novartis Protocol B-356-E-01, A multicenter, openlabel, fixed dose extension to study B-356-E-00 to
prospectively evaluate the long-term safety and
tolerability of CDJN608 monotherapy in subjects
with non-insulin dependent diabetes mellitus
inadequately controlled with diet alone
Novartis Pharmaceuticals Corporation
(12/98 - 5/00)
SmithKline Beecham Protocol BRL 49653C/108
A 16-week randomized, double-blind, parallel group
study to evaluate the safety and efficacy of hypolipidemic
therapy with an HMGCoA reductase inhibitor (Atorvastatin)
in Type 2 diabetes mellitus patients treated with Rosiglitazone
(BRL 49653C) 4 mg BID.
SmithKline Beecham Pharmaceuticals
(5/99 - 7/00)
(3/98 - 7/98)
(10/98 - 1/03)
Pfizer Protocol 217-110-5106
Pfizer Pharmaceuticals
Efficacy and safety of inhaled human insulin therapy in
(10/99 - 5/01)
subjects with Type 2 diabetes mellitus not optimally controlled
with diet and exercise.
Alkermes Protocol ALK17-001
A randomized, parallel-group pharmacokinetic study of
nutropin depot in adults with growth hormone deficiency.
Alkermes, Inc.
(11/99 - 1/01)
Eli Lilly and Company Protocol B9R-EW-TOO2
Eli Lilly and Company
Comparison of an incremental weight-based dose
(2/99 - 5/00)
regimen with an individualised dosage adjusted according
to the IGF-1 response in adults with growth hormone deficiency.
Abbott Medisense Protocol 4350-02-0001
Abbott Medisense
8
Document1
Blood Beta-hydroxybutyrate levels in subjects with type 1 diabetes.
(5/99 - 1/00)
SmithKline Beecham Protocol BRL 49653C/048
SmithKline Beecham Pharmaceuticals
A randomized double-blind study to compare the durability
(4/00 – 6/06)
of glucose lowering and preservation of pancreatic beta-cell
function of rosiglitazone monotherapy compared to metformin
or glyburide/glibenclamide in patients with drug-naive, recently
diagnosed Type 2 diabetes mellitus.
Pfizer Protocol No.217-111
Long term safety of EXUBERA (inhaled insulin): Extension
of therapy in subjects with type 1 or type 2 diabetes mellitus
completing phase III randomized treatment trials.
Pfizer Global Research Development
(5/00 - 1/03)
Takeda Protocol AD-4833/PNFP-341
Takeda Pharmaceuticals America
A double blind, randomized study of the safety and efficacy of a
(9/00 - 11/01)
combination of sulfonylurea and 45 mg of ACTOS (Pioglitazone
HCL) compared to a combination of sulfonylurea and 30 mg of
ACTOS (pioglitazone HCL) in the treatment of patients with
type 2 (non-insulin dependent) diabetes mellitus.
Takeda Protocol AD-4833/PNFP-342
Takeda Pharmaceuticals America
A double blind, randomized study of the safety and efficacy of a
(9/00 - 11/01)
combination of metformin and 45 mg of ACTOS (Pioglitazone
HCL) compared to a combination of metformin and 30 mg of
ACTOS (pioglitazone HCL) in the treatment of patients with
type 2 (non-insulin dependent) diabetes mellitus.
Alkermes/Genentech Protocol Nos. M2378g/ALK03-005
Alkermes/Genentech
A controlled, randomized, parallel-group study of the safety and
efficacy of nutropin depot [somatropin (rDNA) for injectable
suspension] in adults with growth hormone deficiency.
EMD Pharmaceuticals Protocol No. EML016336H201
A Phase II, multicenter, randomized, double-blind, placebocontrolled, parallel group study of CRE 16336 in Type 2
diabetic subjects.
(9/01 - 9/03)
EMD Pharmaceuticals
(1/02 - 4/03)
Novartis Protocol No. CLAF237A2203
Novartis Pharmaceuticals
A 12 week, multicenter, double-blind, randomized, parallel-group,
(4/02 - 9/03)
dose-ranging study to assess the efficacy, safety and tolerability
of LAF237 25 mg bid, 25, 50 or 100 mg od compared to placebo
in patients with type 2 diabetes.
Fujisawa Protocol No. FA614-00004
Fujisawa Research Institute of America
A Randomized, double-blind, placebo controlled trial of FK614 in
(4/02 - 9/03)
type 2 diabetics inadequately controlled on a sulfonylurea.
Novartis Protocol No. CDJN608B2302
Novartis Pharmaceuticals
NAVIGATOR (Nateglinide and Valsartan in Impaired Glucose
`
(4/02 – 10/09)
Tolerance Outcomes Research) A multinational, randomized,
double-blind, placebo-controlled, forced-titration, 2x2 factorial
design study of the efficacy and safety of long term administration
of nateglinide and valsartan in the prevention of diabetes and
9
Document1
cardiovascular outcomes in subjects with impaired glucose
tolerance.
Eli Lilly and Company Protocol No. B9R-MC-GDGA
The global hypopituitary control and complications study.
Eli Lilly and Company
Pfizer Protocol # A2171095: A six month, open-label,
randomized parallel group trial assessing the impact of
dry powder inhaled insulin (Exubera®) on glycemic control
compared to insulin glargine (Lantus®) in patients with
type 2 diabetes mellitus who are poorly controlled
on a combination of two or more oral agents
Pfizer Pharmaceuticals
(12/02 – 9/09)
GlaxoSmithKline Protocol # (KG2110375): A once-daily
GlaxoSmithKline
dose-ranging study of GSK189075 versus placebo in the
treatment of type 2 diabetes mellitus in treatment-naïve subjects
(5/07 - 2009)
(9/07 - 2009)
Amylin Protocol # BCB106: A Randomized,
Amylin Pharmaceuticals
Double-Blind, Parallel-Group, Multicenter Study to Compare
(1/08 – 3/11)
the Glycemic Effects, Safety, and Tolerability of Exenatide
Long-Acting Release to Those of Sitagliptin and Pioglitazone
in Subjects with Type 2 Diabetes Mellitus Treated with Metformin
Diasome Protocol #01-2007-03: An 18-Week
Diasome Pharmaceuticals
Randomized, Double-Blind, Multicenter, Comparator Study
(1/09 – 12/09)
of Two Doses of Oral HDV-Insulin and Placebo with
Background Metformin Treatment in Patients with Type 2 Diabetes Mellitus
Novo Nordisk Protocol #1250-1842: The effect of insulin
Novo Nordisk Pharmaceuticals
detemir in combination with liraglutide and metformin
(4/09 – 1/11)
compared to liraglutide and metformin in subjects with
type 2 diabetes. A 26-week, randomised, open-label,
parallel-group, multicentre, multinational trial with a 26-week extension
Novo Nordisk Protocol #1250-3579: A 52-week randomised, Novo Nordisk Pharmaceuticals
controlled, open label,multicentre, multinational treat-to-target
(8/09 – 12/10)
trial comparing the efficacy and safety of SIBA and insulin
glargine, both injected once daily in combination with oral antidiabetic drugs (OAD), in subjects with type 2 diabetes mellitus
currently treated with OAD(s) and qualifying for more intensified treatment
Novo Nordisk Protocol #1250-3580: A 26 week randomised,
Novo Nordisk Pharmaceuticals
controlled, open label, multicentre, multinational trial
(1/10 – 1/2011)
comparing efficacy and safety of SIBA with sitagliptin as add
on to current oral antidiabetic treatment in insulin-naïve subjects
with type 2 diabetes mellitus inadequately controlled with 1-2
oral antidiabetic drugs (metformin, sulphonylurea, glinides or pioglitazone)
Novo Nordisk Protocol #1250-3643: An extension trial to
Novo Nordisk Pharmaceuticals
NN1250-3579 comparing safety and efficacy of NN1250
(9/10 – 05/2013)
plus OAD(s) with insulin glargine plus OAD(s) in type 2 diabetes:
A 52 week controlled open label, multicentre, multinational,
two-arm, parallel treat-to-target extension trial comparing the
safety and efficiency of SIBA and insulin glargine, both injected
10
Document1
once daily in combination with oral antidiabetic drugs (OAD),
in subjects with type 2 diabetes mellitus after a preceding 52 week
treatment period with SIBA or insulin glargine with OAD(s) in trial NN1250-3579
EFC11319 A randomized, double-blind, placebo-controlled,
parallel-group, multicenter study to evaluate cardiovascular
outcomes during treatment with lixisenatide in type 2 diabetic
patients after an Acute Coronary Syndrome
Sanofi Pharmaceuticals
(01/11 – 05/2013)
Exscel BCB109 A Randomized, Placebo Controlled Clinical
Amylin Pharmaceuticals
Trial to Evaluate Cardiovascular Outcomes After Treatment
(03/11 – present)
with Exenatide Once Weekly in Patients with Type 2 Diabetes
Mellitus Study Name: EXenatide Study of Cardiovascular Event
Lowering Trial (EXSCEL)
(limited to patients with a cardiovascular history beginning 04/11)
Eli Lilly 12R-MC-BIAJ
Eli Lilly Pharmaceuticals
A Comparison of LY2605541 versus Insulin Glargine as
(01/12 – present)
Basal Insulin Treatment in Combination with Oral
Anti-Hyperglycemia Medications in Insulin Naïve Patients with
Type 2 Diabetes Mellitus: A Double-Blind, Randomized Study
(The IMAGINE 2 Study)
Roche NC25608
NC25608 - A Phase 3b, Multi-Center, Double-Blind,
Placebo-Controlled, Parallel Group, Study to Evaluate the
Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events
in Adult Patients with Stable Coronary Heart Disease (CHD),
CHD Risk Equivalents or at Elevated Risk for Cardiovascular
Disease (CVD).
Roche Pharmaceuticals
(01/12 – 07/12)
Novo Nordisk
Novo Nordisk Pharmaceuticals
NN1250-3944: The effect of insulin degludec in combination
(10/12 – 11/2013)
with liraglutide and metformin in subjects with type 2 diabetes
qualifying for treatment intensification
PhaseBio PB1023-PT-CL-0004.0
PhaseBio Pharmaceuticals. Inc.
Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and
(10/12 – 09/2013)
Active-Controlled, Parallel-Group Study to Assess the
Pharmacodynamic Response and Safety and Tolerability of
Three Dose levels of Glymera (PB1023) Injection Following
20 Weeks of Once-Weekly Subcutaneous Dosing in Adult
Subjects with Inadequately Treated Type 2 Diabetes Mellitus
11
Document1
TRAINING AND SPONSORSHIP EXPERIENCE
Rena Vassilopoulou-Sellin, M.D.: Postdoctoral Fellow at Northwestern University; subsequently Professor of
Medicine, University of Texas MD Anderson Cancer Center, Houston, TX
Vina R. Bajaj, M.D.: Postdoctoral Fellow at Northwestern University; then Clinical Instructor in Medicine,
University of Cincinnati School of Medicine
Terry G. Unterman, M.D.: Postdoctoral Fellow at Northwestern University; currently Professor of Medicine,
University of Illinois
Elyse Glaser, M.D.: Postdoctoral Fellow at Emory University; currently in private practice
Guillermo E. Umpierrez, M.D.: Postdoctoral Fellow at Emory University, currently Professor of Medicine,
Emory University
Mushtaq Ahmad, Ph.D.: Postdoctoral Fellow at Emory University; subsequently Assistant Professor of Medicine,
Division of Cardiology, Emory University
David Uhlinger, Ph.D.: Postdoctoral Fellow at Emory University; subsequently Assistant Professor, Department
of Biochemistry, Emory University
Gary Sertich, Ph.D.: Postdoctoral Fellow at Emory University, currently in private practice of patent law.
Janet Klein, Ph.D.: Postdoctoral Fellow at Emory University, subsequently Assistant Professor of Medicine,
Department of Medicine, Emory University
Joyce B. Harp, M.D.: Postdoctoral Fellow at Emory University; subsequently Associate Professor, Department of
Nutrition, University of North Carolina School of Medicine
Thomas R. Ziegler, M.D.: Professor, Department of Medicine, Emory University (Dr. Phillips Sponsor on NIH
Clinical Associate Physician Award 1986-1989)
Betty C. Villafuerte, M.D.: Postdoctoral Fellow, then Assistant Professor at Emory University 1993-2003;
currently Associate Professor, Department of Medicine, University of Louisville (Dr. Phillips Mentor and
Sponsor on NIH Clinical Investigator Award)
Mary Ellen Sweeney, M.D.: Postdoctoral Fellow at Emory University; currently Assistant Professor, Department
of Medicine, Emory University
Peter M. Thulé, M.D.: Postdoctoral Fellow at Emory University, currently Associate Professor, Department of
Medicine, Emory University
Juan-li Zhu, Ph.D.: Postdoctoral Fellow at Emory University, subsequently Research Associate, Department of
Medicine, Emory University
Shouting Huang, Ph.D.: Postdoctoral Fellow at Emory University 1993-1996, subsequently Vice President of
Lao Shi Biomedical Company
Arvind Y. Krishna, M.D.: Postdoctoral Fellow at Emory University; subsequently Assistant Professor of Clinical
Medicine, Northeastern Ohio University College of Medicine.
Edward J. Hunter, Ph.D.: Assistant Professor, Morris Brown College, Atlanta (Dr. Phillips Sponsor on NIH
Minority Investigator Supplement)
Annette M. Bernard, M.D.: Clinical Associate Professor, Department of Medicine, Emory University (Dr. Phillips
Sponsor on Robert Wood Johnson Generalists Faculty Scholars Program Award 1995-1997),
subsequently in private practice
Elizabeth N. Kaytor, Ph.D.: Postdoctoral Fellow at Emory University 1998-2001 (Dr. Phillips Sponsor on NIH
Individual NRSA Award), currently in private practice of patent law
Christopher D. Miller, M.D.: Postdoctoral Fellow at Emory University 1998-2001; subsequently Assistant
Professor, Department of Medicine, Emory University (Dr. Phillips Sponsor on NIH Institutional NRSA
Award); currently Director, Diabetes Program, Bond Clinic, Winter Haven FL
Mary K. Rhee, M.D., M.S.C.R.: Postdoctoral Fellow and Masters of Science in Clinical Research at Emory
University 2001-2004, currently Assistant Professor of Medicine, Emory University (Dr. Phillips Sponsor
on MSCR and NIH Institutional NRSA Award; received individual NRSA Award; Dr. Phillips was
Mentor on NIH Institutional K12 Award; received NIH K23 Award for which Dr. Phillips was Mentor)
Ranee Chatterjee, M.D., M.P.H.: Masters in Public Health at Emory University 2006-2008 (Dr. Phillips was
Mentor), subsequently General Medicine Fellow at Johns Hopkins University School of Medicine,
currently Assistant Professor of Medicine, Duke University School of Medicine
Jennifer G. Twombly, M.D., Ph.D.: Postdoctoral Fellow at Emory University 2008-2010 (Dr. Phillips Sponsor on
NIH individual NRSA Award application), subsequently in private practice
12
Document1
Diana Barb, M.D.: Postdoctoral Fellow at Emory University 2011-2013, currently Assistant Professor of
Medicine, University of Florida School of Medicine
13
Document1
PEER-REVIEW PUBLICATIONS
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
Wurtman, R.J., Axelrod, J., and Phillips, L.S.: Melatonin synthesis in the pineal gland; control by light.
Science 142:1071, 1963.
Phillips, L.S., and Pine, L.: Evaluation of methods used to purify acid-extracted group A streptococcal M
protein. Appl Microbiol 22:963, 1971.
Phillips, L.S., Herington, A.C., and Daughaday, W.H.: Somatomedin stimulation of sulfate incorporation
in porcine costal cartilage discs. Endocrinology 94:856-863, 1974.
Phillips, L.S., and Herington, A.C.: A general bioassay for desktop computer: application to
somatomedin bioassay. Comput Biomed Res 8:362-369, 1975.
Phillips, L.S., Herington, A.C., and Daughaday, W.H.: Steroid hormone effects on somatomedin. I.
Somatomedin action in vitro. Endocrinology 97:780-786, 1975.
Costin, G., Kogut, M.D., Phillips, L.S., and Daughaday, W.H.: Craniopharyngioma: the role of insulin in
promoting post-operative growth. J Clin Endocrinol Metab 42:370-379, 1976.
Herington, A.C., Phillips, L.S., and Daughaday, W.H.: Pituitary regulation of human growth hormone
binding sites in rat liver membranes. Metabolism 25:341-353, 1976.
Phillips, L.S., Herington, A.C., Karl, I.E., and Daughaday, W.H.: Comparison of somatomedin activity in
perfusates of normal and hypophysectomized rat livers with and without added growth hormone.
Endocrinology 98:606-614, 1976.
Herington, A.C., Phillips, L.S., and Daughaday, W.H.: Factors governing the stimulation of embryonic
chick cartilage by somatomedin. Acta Endocrinol 83:259-268, 1976.
Daughaday, W.H., Phillips, L.S., and Mueller, M.C.: The effect of insulin and growth hormone on the
release of somatomedin by the isolated rat liver. Endocrinology 98:1214-1219, 1976.
Phillips, L.S., and Young, H.S.: Nutrition and somatomedin I. Effect of fasting and refeeding on serum
somatomedin activity and cartilage growth activity in rats. Endocrinology 99:304-314, 1976.
Phillips, L.S., and Young, H.S.: Nutrition and somatomedin II. Serum somatomedin activity and
cartilage growth activity in streptozotocin-diabetic rats. Diabetes 25:516-527, 1976.
Pennisi, A.J., Phillips, L.S., Uittenbogaart, C., Ettenger, R.B., Malekzadeh, M.H., and Fine, R.N.: Linear
growth and somatomedin activity in renal allograft recipients. Clin Dialy Trans Forum 6:168-170, 1977.
Pennisi, A.J., Phillips, L.S., Uittenbogaart, C., Ettenger, R.B., Malekzadeh, M.H., and Fine, R.N.:
Nutritional intake, somatomedin activity and linear growth in children undergoing hemodialysis. Proc
Dialy Trans Forum 6:181-183, 1977.
Phillips, L.S., and Orawski, A.T.: Nutrition and somatomedin. III. Diabetic control, somatomedin, and
growth in rats. Diabetes 26:864-869, 1977.
Pennisi, A.J., Costin, G., Phillips, L.S., Uittenbogaart, C., Ettenger, R.B., Malekzadeh, M.H. and Fine,
R.N.: Linear growth in long-term renal allograft recipients. Clin Nephrol 8:415-421, 1977.
Phillips, L.S., Pennisi, A.J., Belosky, D.C., Uittenbogaart, C., Ettenger, R.B., Malekzadeh, M.H. and
Fine, R.N.: Somatomedin activity and inorganic sulfate in children undergoing hemodialysis. J Clin
Endocrinol Metab 46:165-168, 1978.
Green, O.C., Winter, R.J., Kawahara, F.S., Phillips, L.S., Lewy, P.R., Hart, R.L., and Pachman, L.S.:
Pharmocokinetic studies of prednisolone in children. Plasma levels, half-life values and correlation with
physiologic assays for growth and immunity. J Pediat 93:299-303, 1978.
Phillips, L.S., Orawski, A.T., and Belosky, C.D.: Somatomedin and Nutrition. IV. Regulation of
somatomedin activity and growth cartilage activity by quantity and composition of diet in rats.
Endocrinology 103:121-127, 1978.
Chrzanowska, B.L., Nitzan, M., Phillips, L.S., and Schulman, J.D.: Homocysteic acid: An examination
of its possible growth hormone-like activity. Metabolism 28:80-84, 1979.
Phillips, L.S., Belosky, D.C., and Reichard, L.A.: Nutrition and somatomedin. V. Inhibitor(s) in serum
from diabetic rats. Endocrinology 104:1513-1518, 1979.
Phillips, L.S., Belosky, D.C., Young, H.S. and Reichard, L.A.: Nutrition and somatomedin. VI.
Somatomedin activity and somatomedin inhibitory activity in serum from normal and diabetic rats.
Endocrinology 104:1519-1524, 1979.
14
Document1
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
Pennisi, A.J., Costin, G., Phillips, L.S., Malekzadeh, M.H., Ettenger, R.B., and Fine, R.N.: Somatomedin
and growth hormone studies in pediatric renal allograft recipients on daily corticosteroids. Am J Dis
Child 133:950-954, 1979.
Rechler, M.M., Eisen, H.J., Higa, O.Z., Nissley, S.P., Moses, A.C., Schilling, E.E., Fennoy, I., Bruni,
C.B., Phillips, L.S., and Baird, K.L.: Characterization of a somatomedin (insulin-like growth factor)
synthesized by fetal rat liver organ cultures. J Biol Chem 254:7942-7950, 1979.
Phillips, L.S., Vassilipoulou-Sellin, R. and Reichard, L.A.: Nutrition and somatomedin. VIII. The
"somatomedin inhibitor" in diabetic rat serum is a general inhibitor of growing cartilage. Diabetes
28:919-924, 1979.
Winter, R.J., Phillips, L.S., Klein, M.N., Green, O.C., and Traisman, H.S.: Somatomedin activity and
diabetic control in children with insulin-dependent diabetes. Diabetes 28:952-954, 1979.
Winter, R.J., Harris, C.J., Phillips, L.S. and Green, O.C.: Diabetic ketoacidosis: Induction of
hypocalcemia and hypomagnesemia by phosphate therapy. Amer J Med 67:897-900, 1979.
Pennisi, A.J., Ettenger, R.B., Costin, G., Phillips, L.S., Malekzadeh, M.H., Uittenbogaart, C.H., Fine,
R.N.: Somatomedin activity and growth hormone concentration in pediatric renal allograft recipients.
Trans Am Soc Artif Organs 25:455-457, 1979.
Vassilopoulou-Sellin, R., Phillips, L.S., Reichard, L.A.: Nutrition and somatomedin. VII. Regulation of
somatomedin activity by the perfused rat liver. Endocrinology 106:260-267, 1979.
Winter, R.J., Phillips, L.S., Green, O.C., Traisman, H.S.: Somatomedin activity in the Mauriac
syndrome. J Pediatr 97:598-600, 1980.
Phillips, L.S., and Kopple, J.D.: Circulating somatomedin activity and sulfate levels in adults with
normal and impaired kidney function. Metabolism 30:1091-1095, 1981.
Smith, I.F., Latham, M.C., Azubuike, J.A., Butler, W.R., Phillips, L.S., Pond, W.G., and Enwonwu, C.O.:
Blood plasma levels of cortisol, insulin, growth hormone and somatomedin in children with marasmus,
kwashiorkor, and intermediate forms of protein-energy malnutrition. Proc Soc Exp Biol Med 167:607611, 1981.
Bergman, R.N., Phillips, L.S., and Cobelli, C.: Physiologic evaluation of factors controlling glucose
tolerance in man: Measurement of insulin sensitivity and -cell glucose sensitivity from the response to
intravenous glucose. J Clin Invest 68:1456-1467, 1981.
Phillips, L.S., and Scholz, T.D.: Nutrition and somatomedin. IX. Blunting of insulin-like activity by
inhibitor in diabetic rat serum. Diabetes 31:97-106, 1982.
Vassilopoulou-Sellin, R., and Phillips, L.S.: Extraction of somatomedin activity from rat liver.
Endocrinology 110:582-589, 1982.
Phillips, L.S., and Weiss, L.J.: Circulating growth factor studies in growth plate vs. resting cartilage in
vitro. I. Tissue responsiveness. Endocrinology, 111:1255-1262, 1982.
Gray, R.W., Garthwaite, T.L., and Phillips, L.S.: Growth hormone and triiodothyronine permit an
increase in plasma 1,25-(OH)2-D concentrations in response to dietary phosphate deprivation in
hypophysectomized rats. Calcif Tiss Int 35:100-106, 1983.
Phillips, L.S., Weiss, L.J., and Matheson, C.K.: Circulating growth factor studies in growth plate vs.
resting cartilage in vitro. II. Recognition of growth factors in rat serum. Endocrinology 113:1494-1502,
1983.
Phillips, L.S., Bajaj, V.R., Fusco, A.C., and Matheson, C.K.: Nutrition and somatomedin. XI. Studies of
circulating somatomedin inhibitors in rats with streptozotocin-induced diabetes. Diabetes 32:1117-1125,
1983.
Phillips, L.S., Brodsky, I.G., Vassilopoulou-Sellin, R., and Scholz, T.D.: Nutrition and somatomedin. X.
Comparison of insulin-like activity of somatomedins extracted from liver and serum. Metabolism 33:3441, 1984.
Vassilopoulou-Sellin, R., Phillips, L.S., Oyedeji, C.O., and Samaan, N.A.: Metabolic regulation of
somatomedin activity in rat liver. J Endocrinol 101:257-261, 1984.
Phillips, L.S., Fusco, A.C., Unterman, T.G., del Greco, F.: Somatomedin inhibitor in uremia. J Clin
Endocrinol Metab 59:764-772, 1984.
Unterman, T.G., Vazquez, R.M., Slas, A.J., Martyn, P.A., and Phillips, L.S.: Nutrition and somatomedin.
XIII. Usefulness of somatomedin-C in nutritional assessment. Amer J Med 78:228-234, 1985.
15
Document1
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
Goldstein, S., Stivaletta, L.A., and Phillips, L.S.: Separation of somatomedins and somatomedin
inhibitors by size exclusion high-performance liquid chromatography. J Chromatogr 339:388-393, 1985.
Phillips, L.S., Fusco, A.C., and Unterman, T.G.: Nutrition and somatomedin. XIV. Altered levels of
somatomedins and somatomedin inhibitors in rats with streptozotocin-induced diabetes. Metabolism
34:765-770, 1985.
Phillips, L.S., Bajaj, V.R., and Fusco, A.C.: Nutrition and somatomedin. XII. Fractionation of
somatomedins and somatomedin inhibitors in normal and diabetic rats. Int J Biochem 17:597-603, 1985.
Unterman, T.G., and Phillips, L.S.: Glucocorticoid effects on somatomedins and somatomedin inhibitors.
J Clin Endocrinol Metab 61:618-626, 1985.
Umpierrez, G.E., Reed, J.C., Thacker, S.V., and Phillips, L.S.: Preliminary studies of diabetic
decompensation with bedside glucose monitoring techniques. Diabetes Care 9:77-80, 1986.
Phillips, L.S.: Nutrition, somatomedins, and the brain. Metabolism 35:78-87, 1986.
Sadler, T.W., Phillips, L.S., and Goldstein, S.: Inhibition of mouse embryonic growth and development
by a somatomedin inhibitor(s). Diabetes 35:861-865, 1986.
Powell, D., Bergstrom, J., Dzurik, R., Gulyassy, P., Lockwood, D., Phillips, L.S.: Toxins and inhibitors
in chronic renal failure. Am J Kidney Dis, VII, 4:292-299, 1986.
Unterman, T.G. and Phillips, L.S.: Circulating somatomedin activity during hepatic regeneration.
Endocrinology 119:185-192, 1986.
Freinkel, N., Cockroft, D.L., Lewis, N.J., Gorman, L., Akazawa, S., Phillips, L.S., and Shambaugh, G.E.:
Fuel-mediated teratogenesis during early organogenesis: The effects of increased concentrations of
glucose, ketones, or somatomedin inhibitor during rat embryo culture. Am J Clin Nutr 44:986-995, 1986.
Beasley, E.W., III and Phillips, L.S.: Polyuria and refractory hypernatremia after cardiopulmonary arrest.
Am J Med 82:347-349, 1987.
Goldstein, S., Unterman, T.G., Phillips, L.S.: Nutrition and somatomedin. XV. Growth plate growth
factor and biologically active somatomedins in rats with streptozotocin-induced diabetes. Ann Nutr
Metab 31:367-377, 1987.
Glaser, E.W., Goldstein, S., Phillips, L.S.: Nutrition and somatomedin. XVII. Circulating somatomedinC during treatment of diabetic ketoacidosis. Diabetes 36:1152-1160, 1987.
Watts, N.B., Gebhart S.S.P., Clark, R.V., Phillips, L.S.: Postoperative management of diabetes mellitus:
Use of combined infusions of insulin and dextrose. Diabetes Care 10:722-728, 1987.
Phillips, L.S., Goldstein, S., Gavin, III, J.R.: Nutrition and somatomedin XVI. Somatomedins and
somatomedin inhibitors in fasted and refed rats. Metabolism 37:209-216, 1988.
Balkan, W., Rooman, R.P., Hurst-Evans, A., Phillips, L.S., Goldstein, S., Du Caju, M.V.L., Sadler, T.W.:
Somatomedin inhibitors from human serum produce abnormalities in mouse embryos in culture.
Teratology 38:79-86, 1988.
Goldstein, S., Sertich, G., Phillips, L.S., Levan, K.R.: Nutrition and somatomedin. XIX. Molecular
regulation of insulin-like growth factor-1 in streptozotocin-diabetic rats. Molec Endocrinol 2:1093-1100,
1988.
Sadler, T.W., Hunter, III, E.S., Wynn, R.E., Phillips, L.S.: Evidence for a multifactorial origin of
diabetes-induced embryopathies. Diabetes 38:70-74, 1989.
Hofert, J.F., Goldstein, S., Phillips, L.S.: Glucocorticoid effects on IGF-1/somatomedin-C and
somatomedin inhibitor in streptozotocin-diabetic rats. Metabolism 38:594-600, 1989.
Goldstein, S., Phillips, L.S.: Nutrition and somatomedin. XVIII. Nutritionally-regulated release of
somatomedins and somatomedin inhibitors from perfused livers in rats. Metabolism 38:745-752, 1989.
Donahue, S.P., Phillips, L.S.: Nutrition and somatomedin. XX. Response of IGF-1 to nutritional support
in malnourished hospital patients: A possible indicator of short-term changes in nutritional status. Am J
Clin Nutr 50:962-969, 1989.
Umpierrez, G.E., Goldstein, S., Phillips, L.S., Spanheimer, R.G.: Nutritional and hormonal regulation of
collagen production in diabetes. Diabetes 38:758-763, 1989.
Balkan, W., Phillips, L.S., Goldstein, S., Sadler, T.W.: The role of the mouse visceral yolk sac in
nutrition: Inhibition by a somatomedin inhibitor. J Exp Zool 249:36-40, 1989.
Gagliardi, A., Goldstein, S., Phillips, L.S.: Nutrition and somatomedin. XXI. Insulin-like growth factor1 and somatomedin inhibitor in streptozotocin-diabetic rats: Relation to ketogenesis and
gluconeogenesis. Metabolism 39:75-80, 1990.
16
Document1
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
Watts, N.B., Spanheimer, R.G., DiGirolamo, M., Gebhart, S.S.P., Musey, V.C., Siddiq, Y.K., and
Phillips, L.S.: Prediction of glucose response to weight loss in patients with non-insulin dependent
diabetes mellitus. Arch Int Med 150:803-806, 1990.
Welch, S., Gebhart, S.S.P., Bergman, R.N., and Phillips, L.S.: Minimal model analysis of IVGTTderived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab 71:1508-1518, 1990.
Almeida-Andrade, H., Gagliardi, A.R.T., Motta, L.A.C.R., Baldissera, S.F., Favaretto, A.L.V., AntunesRodrigues, J., and Phillips, L.S.: Effect of clonidine on growth and plasma somatomedin C levels of
young rats. Brazilian J Med Biol Res 23:1033-1036, 1990.
Goldstein, S., Harp, J.B., Phillips, L.S.: Nutrition and somatomedin. XXII. Molecular regulation of
insulin-like growth factor-1 during fasting and refeeding in rats. J Molec Endocrinol 6:33-43, 1991.
Harp, J.B., Goldstein, S., Phillips, L.S.: Nutrition and somatomedin. XXIII. Molecular regulation of
IGF-1 by amino acid availability in cultured hepatocytes. Diabetes 40:95-101, 1991.
Goldstein, S., Phillips, L.S.: Extraction and nutritional/hormonal regulation of tissue insulin-like growth
factor 1 activity. J Biol Chem 266:14725-14731, 1991.
Hunter, E.S.,III, Phillips, L.S., Goldstein, S, and Sadler, T.W.: Altered visceral yolk sac function
produced by a low molecular weight somatomedin inhibitor. Teratology 43:331-340, 1991.
Villafuerte, B.C., Goldstein, S., Murphy, L.J., and Phillips, L.S.: Nutrition and somatomedin XXV.
Regulation of insulin-like growth factor binding protein-1 in primary cultures of normal rat hepatocytes.
Diabetes 40:837-841, 1991.
Graubert, M.G., Goldstein, S., and Phillips, L.S.: Nutrition and somatomedin XXVII. Total and "free"
insulin-like growth factor 1 and IGF binding proteins in rats with streptozotocin-induced diabetes.
Diabetes 40:959-965, 1991.
Phillips, L.S., Goldstein, S., and Pao, C.-I.: Nutrition and somatomedin XXVI. Molecular regulation of
insulin-like growth factor-1 by insulin in cultured rat hepatocytes. Diabetes 40:1525-1530, 1991.
Villafuerte, B., Goldstein, S., Robertson, D.G., Pao, C-I., Murphy, L.J., and Phillips, L.S.: Nutrition and
somatomedin XXVIII. Molecular regulation of insulin-like growth factor binding protein-1 in cultured
rat hepatocytes. Diabetes 41:835-842, 1992.
Pao, C-I., Farmer, P.K., Begovic, S., Goldstein, S., Wu, G-J., and Phillips, L.S.: Expression of hepatic
insulin-like growth factor-1 and insulin-like growth factor binding protein-1 genes is transcriptionally
regulated in streptozotocin-diabetic rats. Molecular Endocrinology 6:969-977, 1992.
Musey, V.C., Moore, P.B., Goldstein, S., Farmer, P.D., and Phillips, L.S.: Nutrition and somatomedin
XXIX. Differential regulation of insulin-like growth factor-1 and an IGF-binding protein by dietary
composition in man. Am J Med Sci 305:131-138, 1993.
Weber, C.J., Vansant, J., Alazaraki, N., Christy, J., Watts, N.B., Gebhart, S.S.P., Phillips, L.S., Thule,
P.M., Sewell, W., and McGarity, W.C.: The value of technetium 99m sestamibi-iodine123 imaging (TSI)
in reoperative parathyroid surgery. Surgery 114:1011-1018, 1993.
Pao, C-I., Farmer, P.K., Begovic, S., Villafuerte, B.C., Wu, G-J., Robertson, D.G., and Phillips, L.S.:
Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding protein 1 gene transcription by
hormones and provision of amino acids in rat hepatocytes. Molecular Endocrinology 7:1561-1568, 1993.
Thule, P., Thakore, K., Vansant, J., McGarity, W., Weber, C., and Phillips, L.S.: Preoperative
localization of parathyroid tissue with technetium-99m sestamibi 123I subtraction scanning. J Clin
Endocrinol Metab 78:77-82, 1994.
Villafuerte, B.C., Koop, B.L., Gu, L., Pao, C-I., Birdsong, G.G., and Phillips, L.S.: Co-culture of primary
rat hepatocytes with non-parenchymal cells permits expression of insulin-like growth factor binding
protein-3. Endocrinology 134:2044-2050, 1994.
Umpierrez, G.E., Watts, N.B., Mixon, P.S., and Phillips, L.S.: Clinical utility of bedside measurement of
β-hydroxybutyrate in the management of diabetic ketoacidosis. Diabetes Care 18:137-138, 1995.
Huang, S., Thulé, P.M., and Phillips, L.S.: Identification of novel promoter and repressor elements in the
5'-flanking regions of the rat insulin-like growth factor-1 gene. Biochem Biophys Res Commun 206:279286, 1995.
Musey, V.C., Lee, J.K., Crawford, R., Klatka, M.A., McAdams, D., and Phillips, L.S.: Diabetes in Urban
African-Americans. I. Cessation of insulin therapy is the major precipitating cause of diabetic
ketoacidosis. Diabetes Care 18:483-489, 1995.
17
Document1
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
Villafuerte, B.C., Koop, B.L., Pao, C-I., and Phillips, L.S.: Glucocorticoid regulation of insulin-like
growth factor binding protein-3. Endocrinology 136:1928-1933, 1995.
Goldschmid, M.G., Domin, W.S., Ziemer, D.C., Gallina, D.L., and Phillips, L.S.: Diabetes in Urban
African-Americans. II. High prevalence of microalbuminuria and nephropathy in African-Americans with
diabetes. Diabetes Care 18:955-961, 1995.
Pao, C.-I, Zhu, J.-L., Farmer, P.K., Robertson, D.G., Begovic, S., Wu, G.-J., and Phillips, L.S.:
Transcriptional regulation of the rat insulin-like growth factor-I gene involves metabolism-dependent
binding of nuclear proteins to a downstream region. J Biol Chem 270:24917-24923, 1995.
Umpierrez, G.E., Casals, M.M.C., Gebhart, S.S.P., Mixon, P.S., Clark, W.S., and Phillips, L.S.: Diabetic
ketoacidosis in obese African-Americans. Diabetes 44:790-795, 1995.
Pao, C.-I, Lin, K.M., Zhu, J-L., Wu, G-J., Farmer, P.K., and Phillips, L.S.: In vitro transcription of the rat
insulin-like growth factor-I gene. J Biol Chem 271:8667-8674, 1996.
Ziemer, D.C., Goldschmid, M., Musey, V.C., Domin, W.S., Gallina, D.L. and Phillips, L.S.: Diabetes in
Urban African-Americans. III. Metabolic control of Type II diabetes in a municipal hospital setting. Am
J Med 101:25-33, 1996.
Villafuerte, B.C., Zhang, W-N., and Phillips, L.S.: Insulin and IGF-I regulate hepatic insulin-like growth
factor binding protein-3 (IGFBP-3) by different mechanisms. Molecular Endocrinology 10:622-630,
1996.
El-Kebbi, I.M., Bacha, G.A., Ziemer, D.C., Musey, V.C., Gallina, D.L., and Phillips, L.S.: Diabetes in
Urban African-Americans. V. Use of discussion groups to identify barriers to dietary therapy. The
Diabetes Educator 22:488-492, 1996.
Price, S.R., Bailey, J.L., Wang, X., Jurkovitz, C., England, B.K., Ding, X., Phillips, L.S., and Mitch, W.E.
Muscle wasting in insulinopenic rats results from activation of the ATP-dependent, ubiquitin-proteasome
proteolytic pathway by a mechanism including gene transcription. J Clin Invest 98:1703-1708, 1996.
Krishna, A.Y., Pao, C.-I, Thulé, P.M., Villafuerte, B.C., and Phillips, L.S.: Transcription initiation of the
insulin-like growth factor-I gene in hepatocyte primary culture. J Endocrinol 151:215-223, 1996.
El-Kebbi, I.M., Ziemer, D.C., Gallina, D.L., Musey, V.C., and Phillips, L.S. Diabetes in Urban AfricanAmericans. IX. Analysis of practitioner adherence to diabetes management protocols. Diabetes Care
20:698-703, 1997.
Villafuerte, B.C., Zhao, W., Herington, A.C., Saffery, R. and Phillips, L.S. Identification of an insulinresponsive element in the rat insulin-like growth factor binding protein-3 gene. J Biol Chem 272:50245030, 1997.
Anderson, L.A., Ziemer, D.C., Janes, G., and Phillips, L.S. Diabetes in Urban African-Americans. VII.
Body-image perceptions and satisfaction among African-American women and men with diabetes. The
Diabetes Educator 23:301-308, 1997.
Nurss, J.R., El-Kebbi, I.M., Gallina, D.L., Ziemer, D.C., Musey, V.C., Lewis, S., Liao, Q., and Phillips,
L.S.: Diabetes in Urban African-Americans. VIII. Functional health literacy of patients with Type II
diabetes. The Diabetes Educator 23:563-568, 1997.
El-Kebbi, I.M., Ziemer, D.C., Musey, V.C., Gallina, D.L., and Phillips, L.S.: Diabetes in Urban AfricanAmericans. VI. Utility of fasting or random glucose in identifying poor glycemic control. Diabetes Care
21:501-505,1998.
Kahn, H.S., Dunbar, V.G., Ziemer, D.C., and Phillips, L.S. Diabetes in Urban African-Americans. XII.
Anthropometry for recognizing high C-peptide/glucose levels in patients recently diagnosed with noninsulin-dependent diabetes mellitus. Obes Res 6:238-245, 1998.
Thaler, L.M., El-Kebbi, I.M., Ziemer, D.C., Gallina, D.L., Dunbar, V.G., Phillips, L.S. High prevalence
of albuminuria among African-Americans with short duration of diabetes. Diabetes Care 21:1576-1577,
1998.
Bernard, A.M., Anderson, L.A., Cook, C.B., and Phillips, L.S. What do internal medicine residents need
to enhance their diabetes care? Diabetes Care 22:661-666, 1999.
El-Kebbi, I.M., Gallina, D.L., Dunbar, V.G., Phillips, L.S. Diabetes in Urban African-Americans. XV.
Identification of barriers to provider adherence to management protocols. Diabetes Care 22:1617-1620,
1999.
Haughton, C.L., Dillehay, D.L. and Phillips, L.S. Insulin replacement therapy for the rat model of
streptozotocin-induced diabetes mellitus. Laboratory Animal Science 49:639-644, 1999.
18
Document1
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
Thaler, L.M., Ziemer, D.C., Gallina, D.L., Cook, C.B., Dunbar, V.G., Phillips, L.S., El-Kebbi, I.M.
Diabetes in Urban African-Americans. XVII. Availability of rapid HbA1c measurements enhances
clinical decision-making. Diabetes Care 22:1415-1421, 1999.
Cook, C.B., Ziemer, D.C., El-Kebbi, I.M., Gallina, D.L., Dunbar, V.G., Ernst, K.L., Phillips, L.S.
Diabetes in Urban African-Americans. XVI. Overcoming clinical inertia improves glycemic control in
patients with type 2 diabetes. Diabetes Care 22:1494-1500, 1999.
Zhu, J-L., Pao, C.-I, Hunter, E., Jr., Lin, K.M., Wu, G-J., and Phillips, L.S.: Identification of core
sequences involved in metabolism-dependent nuclear protein binding to the rat insulin-like growth factor
I gene. Endocrinology 140:4761-4771, 1999.
Hayes, R.P., Bernard, A.M., Slocum, W., El-Kebbi, I.M., Ziemer, D.C., Gallina, D.L., Phillips, L.S.
Diabetes in Urban African-Americans. XIII. Measurement of diabetes-specific locus of control in a
population with Type 2 diabetes. The Diabetes Educator 26:121-128,2000.
Thulé, P.M., Phillips, L.S., Liu, J-M. Glucose regulated production of human insulin in rat hepatocytes.
Gene Therapy 7:205-214, 2000.
Thaler, L.M., Ziemer, D.C., El-Kebbi, I.M., Gallina, D.L., Cook, C.B. and Phillips, L.S. Diabetes in
Urban African-Americans. XIX. Prediction of the need for pharmacologic therapy. Diabetes Care
23:820-825, 2000.
Miller, C.D., Phillips, L.S., Tate, M.K., Porwoll, J.M., Rossman, S.D., Cronmiller, N., Gebhart, S.S.P.
Meeting ADA guidelines in endocrinologist practice. Diabetes Care 23:444-448, 2000.
Zhu, J-L, Pao, C-I, Kaytor, E.N., Phillips, LS. Involvement of Sp1 in the transcriptional regulation of the
rat insulin-like growth factor-1 gene. Molec Cell Endo 164:205-218, 2000.
Cook, C.B., Erdman, D.M., Ryan, G.J., Greenlund, K.J., Giles, W.H., Gallina, D.L., El-Kebbi, I, Ziemer,
D.C., Ernst, K.L., Dunbar, V.G., Phillips, L.S. The pattern of dyslipidemia among urban African
Americans with Type 2 diabetes. Diabetes Care 23:319-324, 2000.
Trainer, P.J., Drake, W.M., Katznelson, L., Freda, P.U., Herman-Bonert, V., van der Lely, A.J., Dimaraki,
E.V., Stewart, P.M., Friend, K.E., Vance, M.L., Besser, G.M., Thorner, M.O., Parkinson, C., Klibanski,
A., Powell, J.S., Melmed, S., Barkan, A.L., Sheppard, M.C., Maldonado, M., Rose, R., Clemmons, D.R.,
Johannsson, G., Bengtsson, B-A., Stavrou, S., Kleinberg, D.L., Cook, D.M., Phillips, L.S., Bidlingmaier,
M., Strasburger, C.J., Zib, K., Hackett, S., Bennett, W.F., Davis, R.J., Scarlett, J.A. Treatment of
acromegaly with pegvisomant, a genetically-engineered human growth hormone receptor antagonist. N
Engl J Med 342:1171-1177, 2000.
Cook, C.B., Lyles, R.H., El-Kebbi, I.M., Ziemer, D.C., Gallina, D.L., Dunbar, V.G., Phillips, L.S. The
potentially poor response to outpatient diabetes care in urban African-Americans. Diabetes Care 24: 209215, 2001.
El-Kebbi, I.M., Ziemer, D.C., Cook, C.B., Miller, C.D., Gallina, D.L., Phillips, L.S. Cormorbidity and
glycemic control in patients with Type 2 diabetes. Arch Int Med 161: 1295-1300, 2001.
Kaytor, E.N., Zhu, J.L., Pao, C-I, Phillips, L.S. Physiological concentrations of insulin promote binding
of nuclear proteins to the IGF-I gene. Endocrinology 142: 1041-1049, 2001.
Miller, C.D., Phillips, L.S., Ziemer, D.C., Gallina, D.L., Cook, C.B., El-Kebbi, I.M. Hypoglycemia in
patients with Type 2 diabetes. Arch Int Med 161: 1653-1659, 2001.
Phillips, L.S., Branch, W.T. Jr., Cook, C.B., Doyle, J.P., El-Kebbi, I.M., Gallina, D.L., Miller, C.D.,
Ziemer, D.C., Barnes, C.S. Clinical inertia. Annals of Internal Medicine 135: 825-834, 2001.
Phillips, L.S., Grunberger, G., Miller, E., Patwardhan, R., Rappaport, E.B., Salzman, A., for the
Rosiglitazone Clinical Trials Study Group: Once- and twice-daily dosing with rosiglitazone improves
glycemic control in patients with Type 2 diabetes. Diabetes Care 24: 308-315, 2001.
Kaytor, E.N., Zhu, J.L., Pao, C.-I., Phillips, L.S. Insulin-responsive nuclear proteins facilitate Sp1
interactions with the IGF-I gene. J Biol Chem 276: 36896-36901, 2001.
van der Lely, A.J., Hutson, R.K., Trainer, P.J., Besser, G.M., Barkan, A.L., Katznelson, L., Klibanski,
A.., Herman-Bonert, V., Melmed, S., Vance, M.L., Freda, P.U., Stewar,t P.M., Friend, K.E., Clemmons,
D.R., Johannsson, G., Stavrou, S., Cook. D.M., Phillips, L.S., Strasburger, C.J., Hackett, S., Zib, K.A.,
Davis, R.J., Scarlett, J.A., Thorner, M.O. Long-term treatment of acromegaly with pegvisomant, a growth
hormone receptor antagonist. Lancet 358: 1754-9, 2001.
Phillips, L.S., Cook, C.B, El-Kebbi, I.M., Gallina, D.L., Ziemer, D.C., Miller, C.D., Doyle, J.P., Hayes,
R.P., Thompson, D.N., Ballard, D.J., Barnes, C.S., Slocum, W., Hertzberg, V.S., Lyles, R.H., McClellan,
19
Document1
127.
128.
129.
130.
131.
132.
133.
134.
135.
136.
137.
138.
139.
140.
141.
142.
W.M., Branch, W.T., Jr. The Improving Primary Care of African Americans with Diabetes (IPCAAD)
Project: Rationale and Design. Controlled Clinical Trials 23: 554-569, 2002.
Erdman, D.M., Cook, C.B., Greenlund, K.J., Giles, W.H., El-Kebbi, I.M., Ryan, G.J., Gallina, D.L.,
Ziemer, D.C., Dunbar, V.G., Phillips, L.S. The impact of outpatient diabetes management on serum
lipids in urban African Americans with type 2 diabetes. Diabetes Care 25: 9-15, 2002.
Cook, D.M., Biller, B., Vance, M.L., Hoffman, A.R., Phillips, L.S., Ford, K.M., Benziger, D.P.,
Illeperuma, A., Blethen, S.L., Attie, K.M., Dao, L.N., Reimann, J.D., Fielder, P.J. The pharmacokinetic
and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (Nutropin
Depot) in GH-deficient adults. J Clin Endocr Metab 87: 4508-4514, 2002.
Miller, C.D., Barnes, C.S., Phillips, L.S., Ziemer, D.C., Gallina, D.L., Cook, C.B., El-Kebbi, I.M. Rapid
A1c availability improves clinical decision-making in an urban primary care clinic. Diabetes Care 26:
1158-1163, 2003.
El-Kebbi, I.M., Cook, C.B., Ziemer, D.C., Miller, C.D., Gallina, D.L., Phillips, L.S. Association of
younger age as a risk factor for poor glycemic control and obesity in urban African-Americans with type
2 diabetes. Arch Int Med 163: 69-75, 2003.
Delea, T.E., Hagiwara, M., Edelsberg, J.S., Oster, G., Phillips, L.S. Use of thiazolidinediones and risk of
heart failure in persons with type 2 diabetes mellitus: a retrospective observational cohort study. Diab
Care 26: 2983-2989, 2003.
Ziemer, D.C., Berkowitz, K.J., Panayioto, R.M., El-Kebbi, I.M., Musey, V.C., Anderson, L.A., Wanko,
N.S., Fowke, M.L., Brazier, C.W., Dunbar, V.G., Slocum, W., Bacha, G.A., Gallina, D.L., and Phillips,
L.S. A simple meal plan emphasizing healthy food choices is as effective as an exchange-based meal
plan for urban African-Americans with type 2 diabetes. Diabetes Care 26: 1719-1724, 2003.
Dunlop, B.W., Sternberg, M., Phillips, L.S., Stephenson, J., Duncan, E. Disturbed glucose metabolism
among patients taking olanzapine and typical antipsychotics. Psychopharm Bull 37: 99-117, 2003.
Barnes, C. S., Ziemer, D.C., Miller, C.D., Doyle, J.P., Watkins, C. Jr., Cook, C.B., Gallina, D.L., ElKebbi, I.M., Branch, W.T. Jr., Phillips, L.S. There is little time for diabetes management in the primary
care setting (IPCAAD 4). The Diabetes Educator 30: 126-135, 2004.
Villafuerte, B.C., Phillips, L.S., Zhao, W., Rane, M.J. Insulin response element binding protein-1: A
novel Akt substrate involved in transcriptional action of insulin. J Biol Chem 279: 36650-36659, 2004.
El-Kebbi, I.M., Ziemer, D.C., Cook, C.B., Gallina, D.L., Barnes, C.S., Phillips, L.S. Utility of casual
post-prandial glucose levels in type 2 diabetes management. Diab Care 27: 335-339, 2004.
Hoffman, A.R., Kuntze, J.E., Baptista, J., Baum, H., Baumann, G.P., Biller, B.M.K., Clark, R.V., Cook,
D., Inzucchi, S.E., Kleinberg, D., Klibanski, A., Lieberman, S.A., Marcus, R., Melmed, S., Neuman, C.,
Phillips, L.S., Ridgway, E.C., Robbins, R., Schlechte, J., Sharma, M., Snyder, Pl, Thorner, M., Vance,
M.L. Growth hormone (GH) replacement therapy in adult-onset GH deficiency: effects on body
composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endo
Metab 89: 2048-56, 2004.
Hsia, J., Criqui, M.H., Rodabaugh, R.J., Langer, R.D., Phillips, L.S., Allison, M., Bonds, D., Masaki, K.,
Caralis, P., Kotchen, J.; Women's Health Initiative Investigators. Estrogen Plus Progestin and the Risk of
Peripheral Arterial Disease: the Women's Health Initiative. Circulation 109: 620-626, 2004.
The Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in
postmenopausal women with hysterectomy. The Women’s Health Initiative randomized controlled trial.
JAMA 291: 1701-1712, 2004.
Margolis, K.L., Bonds, D.E., Rodabaugh, R.J., Tinker, L., Phillips, L.S., Allen, C., Bassford, T., Burke,
G., Torrens, J., Howard, B.V. Effect of oestrogen plus progestin on the incidence of diabetes in
postmenopausal women: results from the Women’s Health Initiative Hormone Trial. Diabetologia 47:
1175-1187, 2004.
Rhee, M.K., Slocum, W.P., Ziemer, D.C., Culler, S.D., Cook, C.B., El-Kebbi, I.M., Gallina, D.L., Barnes,
C.S., Phillips, L.S. Patient adherence improves glycemic control. The Diabetes Educator 31: 240-250,
2005.
Rhee, M.K., Cook, C.B., Dunbar, V.G., Panayioto, R. Berkowitz, K., Boyd, B., Broussard, S., George, C.,
El-Kebbi, I.M., Lyles, R.H., Phillips, L.S. Limited healthcare access impairs glycemic control in urban
African Americans with type 2 diabetes. J Health Care Poor and Underserved 16: 734-736, 2005.
20
Document1
143.
144.
145.
146.
147.
148.
149.
150.
151.
152.
153.
154.
155.
156.
157.
158.
159.
160.
Miller, C.D., Ziemer, D.C., El-Kebbi, I.M., Cook, C.B., Gallina, D.L., Doyle, J.P., Phillips, L.S. Use of a
“glucose algorithm” to direct diabetes therapy improves A1c outcomes and defines an approach to assess
provider behavior. The Diabetes Educator 32: 533-545, 2006.
Rhee, M.K., Ziemer, D.C., Phillips, L.S. Postchallenge glucose rises with increasing age even when
glucose tolerance is normal. Diabet Med 23: 1174-1179, 2006.
Phillips, L.S., Ziemer, D.C., Doyle, J.P., Barnes. C.S., Kolm, P., Branch, W.T., Caudle, J.M., Cook, C.B.,
Dunbar, V.G., El-Kebbi, I.M., Gallina, D.L., Hayes, R.P., Miller, C.D., Rhee, M.K., Thompson, D.M.,
Watkins C. An endocrinologist-supported intervention aimed at providers improves diabetes
management in a primary care site. IPCAAD 7. Diab Care 28: 2352-2360, 2005.
DeFronzo, R.A., Bergenstal, R.M., Cefalu, W.T., Pullman, J., Lerman, S., Bode, B.W., Phillips, L.S.
Efficacy of inhaled insulin in patients with type 2 diabetes mellitus not optimally controlled with diet and
exercise: a 12-week, randomized, comparative trial. Diab Care 28: 1922-1928, 2005.
Miller, C.D., Ziemer, D.C., Doyle, J.P., Cook, C.B., El-Kebbi, I.M., Gallina, D.L., Watkins, C. Jr.,
Barnes, C.S., Walker, G.D., Lyles, R.H., Hertzberg, V.S., McClellan, W.M., Branch, W.T. Jr., Phillips,
L.S. Diabetes management by residents in training at a municipal hospital primary care site (IPCAAD 2).
Ethnicity and Disease 15: 649-655, 2005.
Ziemer, D.C., Miller, C.D., Rhee, M.K., Doyle, J.P., Watkins, C. Jr., Cook, C.B., Gallina, D.L., El-Kebbi,
I.M., Barnes, C. S., Dunbar, V.G., Branch, W.T. Jr., Phillips, L.S. Clinical inertia contributes to poor
diabetes control in a primary care site compared to a specialized diabetes clinic (IPCAAD 3). The
Diabetes Educator 31: 564-571, 2005.
Bonds, D.E., Lasser, L., Qi, L., Rbzyski, R., Caan, B., Heiss, G., Lieu, J.H., Mason, E., Oberman, A.,
O’Sullivan, M.J., Phillips, L.S., Prineas, R., Tinker, L. Effect of conjugated equine oestrogen alone on
diabetes incidence: the results of the Women’s Health Initiative. Diabetologia 49: 459-468, 2006.
Ziemer, D.C., Doyle, J.P., Barnes, C. S., Branch, W.T. Jr., Cook, C.B., El-Kebbi, I.M., Gallina, D.L.,
Kolm, P., Rhee, M.K., Phillips, L.S. An intervention to overcome clinical inertia and improve diabetes
control in a primary care setting. IPCAAD 8. Arch Int Med 166: 507-513, 2006.
The Women’s Health Initiative Steering Committee. Low-fat dietary pattern and risk of invasive breast
cancer. The Women’s Health Initiative randomized controlled dietary modification trial. JAMA 295:
629-642, 2006.
The Women’s Health Initiative Steering Committee. Low-fat dietary pattern and risk of colorectal
cancer. The Women’s Health Initiative randomized controlled dietary modification trial. JAMA 295:
643-654, 2006.
The Women’s Health Initiative Steering Committee. Low-fat dietary pattern and risk of cardiovascular
disease. The Women’s Health Initiative randomized controlled dietary modification trial. JAMA 295:
655-666, 2006.
The Women’s Health Initiative Steering Committee. Calcium plus vitamin D supplementation and the
risk of colorectal cancer. New Eng J Med 354: 684-696, 2006.
The Women’s Health Initiative Steering Committee. Calcium plus vitamin D supplementation and the
risk of fractures. New Eng J Med 354: 669-683, 2006.
Phillips, L.S., Weintraub, W.S., Ziemer, D.C., Kolm, P., Foster, J.K., Vaccarino, V., Rhee, Budhwani,
R.H., Caudle, J.M. All prediabetes is not the same: metabolic and vascular risks of impaired fasting glucose at
100 vs. 110 mg/dl. The Screening for Impaired Glucose Tolerance Study 1 (SIGT 1). Diab Care 29:
1405-1407, 2006.
Lin, E., Phillips, L.S., Ziegler, T.R., Schmotzer, B., Wu, K., Li, H.., Khaitan, L., Lynch, S.A., Torres,
W.E., Smith, C.D., Gletsu-Miller, N. Increases in adiponectin predict improved liver, but not peripheral,
insulin sensitivity in severely obese women during weight loss. Diabetes 56: 735-742, 2007.
Duncan, E., Dunlop, B.W., Boshoven, W., Woolson, S.L., Hamer, R.M., Phillips, L.S. Relative risk of
glucose elevation during antipsychotic exposure in a Veterans Administration population. Int Clin
Psychopharmacol. 22: 1-11, 2007.
The Women’s Health Initiative Investigators and the WHI Coronary-Artery Calcium Study Investigators.
Estrogen therapy and coronary-artery calcification. New Eng J Med 356: 2591-2602, 2007.
Ziemer, D.C., Kolm, P., Foster, J.K., Weintraub, W.S., Vaccarino, V., Rhee, Varughese, R.M., Tsui,
C.W., Koch, D.D., Twombly, J.G., Narayan, K.M. Venkat, Phillips, L.S. Random plasma glucose in
serendipitous screening for glucose intolerance. SIGT 2. J Gen Int Med 23: 528-535, 2008.
21
Document1
161.
162.
163.
164.
165.
166.
167.
168.
169.
170.
171.
172.
173.
174.
175.
176.
177.
178.
Rhee, M.K., Ziemer, D.C., Caudle, J.M., Kolm, P., Phillips, L.S. Use of a uniform treatment algorithm
abolishes racial disparities in glycemic control. The Diab Educator 34: 665-663, 2008.
Rhee, M.K., Musselman, D., Weintraub, W.S., Ziemer, D.C., Kolm, P., Vaccarino, V., Caudle, J.M.,
Varughese, R.M., Irving, J.M., Phillips, L.S. Unrecognized glucose Intolerance is not associated with
depression. Diab Med 25: 1361-1365, 2008.
Ziemer, D.C., Kolm, P., Weintraub, W.S., Vaccarino, V., Rhee, M.K., Caudle, J.M., Irving, J.M., Koch,
D.D., Narayan, V.K.M., Phillips, L.S. Age, BMI, and race are less important than random plasma
glucose to identify risk of glucose intolerance. SIGT 5. Diab Care 31: 884-886, 2008.
Ader, M., Garvey, W.T., Phillips, L.S., Nemeroff, C.B., Gharabawi, G., Mahmoud, R., Greenspan, A.,
Berry, S.A., Musselman, D.L., Morein, J., Zhu, Y., Mao, L., Bergman, R.N. Ethnic heterogeneity in
glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. J
Psychiat Res 42: 1076-1085, 2008.
Allison, M.A., Manson, J.E., Langer, R.D., Can, J.J., Rossouw, J.E., Pettinger, M.B., Phillips, L.S.,
Cochrane, B.B., Eaton, C.B., Greenland, P., Hendrix, S., Hsia, J., Hunt, J.R., Jackson, R.D., Johnson,
K.C., Kuller, L.H., Robinson, J. Oophorectomy, hormone therapy and subclinical coronary artery disease
in women with hysterectomy: The Women’s Health Initiative Coronary Artery Calcium Study.
Menopause 15: 639-647, 2008.
El Bassuoni, E.A., Ziemer, D.C., Kolm, P., Rhee, M.K., Vaccarino, V., Tsui, C.W., Kaufman, J.A.,
Osinski, G.E., Koch, D.D., Narayan, V.K.M., Weintraub, W.S., Phillips, L.S. The “metabolic syndrome”
is less useful than random plasma glucose to screen for glucose intolerance. SIGT 4. Prim Care Diab 2:
147-153, 2008.
The Women’s Health Initiative Steering Committee. Health risks and benefits 3 years after stopping
randomized treatment with estrogen and progestin. JAMA 299: 1036-1045, 2008.
Zhang, Q., Tang, N., Schepmoes, A., Phillips, L.S., Smith, R.D., Metz, T.O. Proteomic profiling of nonenzymatically glycated proteins in human plasma and erythrocyte membranes. J Proteome Res 7: 20252032, 2008.
Margolis, K.L., Qi, L., Brzyski, R., Bonds, D.E., Howard, B.V., Kempainen, S., Liu, S., Robinson, J.G.,
Safford, M.M., Tinker, L.T., Phillips, L.S. Validity of diabetes self-reports in the Women’s Health
Initiative: comparison with medication inventories and fasting glucose measurements. Clinical Trials 5:
240-247, 2008.
Phillips, L.S., Ziemer, D.C., Kolm, P., Weintraub, W.S., Vaccarino, V., Rhee, M.K., Chatterjee, R.,
Narayan, V.K.M., Koch, D.D. Glucose challenge test screening for prediabetes and undiagnosed
diabetes: SIGT 6. Diabetologia 52: 1798-1807, 2009.
Umpierrez, G.E., Smiley, D., Robalino, G., Peng, L., Kitabchi, A.E., Khan, B., Le, A., Brown, V.,
Phillips, L.S. Intravenous intralipid-induced blood pressure elevation and endothelial dysfunction in
obese African-Americans with type 2 diabetes. J Clin Endocrinol Metab 94: 609-614, 2009.
Chatterjee, R., Narayan, V.K.M., Lipscomb, J., Phillips, L.S. Screening for prediabetes and diabetes may
be cost-saving: SIGT 7. Diab Care 33: 1484-1490, 2010.
Ziemer, D.C., El-Kebbi, I.M., Umpierrez, G.E., Rhee, M.K., Phillips, L.S., Cook, C.B. Diabetes
management in urban African Americans: review of a public hospital experience. Ethn Dis 18: 336-341,
2008.
Rhee, M.K., Ziemer, D.C., Kolm, P., Vaccarino, V., Weintraub, W.S., Narayan, V.K.M., Kolm, P.,
Twombly, J.G., Phillips, L.S. Many Americans have prediabetes and should be considered for metformin
therapy. SIGT 11. Diab Care 33: 49-54, 2010.
Fraser, L-A., Twombly, J.G., Zhu, M., Long, Q., Hanfelt, J.J., Narayan, K.M.V., Wilson, P.W.F., Phillips,
L.S. Delay in diagnosis of diabetes is not the patient's fault. Diab Care 33: e10 (DOI: 10.2337/dc091129), 2010.
Twombly, J.G., Long, Q., Zhu, M., Wilson, P.W.F., Narayan, K.M.V., Fraser, L-A., Webber, B.C.,
Phillips, L.S. Diabetes care in black and white veterans in the southeastern United States. Diab Care 33:
958-963, 2010.
Ziemer, D.C., Kolm, P., Weintraub, W.S., Vaccarino, V., Rhee, M.K., Twombly, J.G., Narayan, K.M.V.,
Koch, D.D., Phillips, L.S. Glucose-independent, black-white differences in hemoglobin A1c levels. Ann
Int Med 152: 770-777, 2010.
Fareed, A., Musselman, D., Byrd-Sellers, J., Barnet III, G., Vayalapalli, S., Casarella, J., Drexler, K.,
22
Document1
179.
180.
181.
182.
183.
184.
185.
186.
187.
188.
189.
190.
191.
192.
193.
194.
Phillips, L.S. On-site basic health screening and brief health counseling of chronic medical conditions for
veterans in methadone maintenance treatment. J Addiction Med 4: 160-166, 2010.
Colenda, C.C., Legault, C., Rapp, S.R., DeBon, M.W., Hogan, P., Wallace, R., Hershey, L., Ockene, J.,
Whitmer, R., Phillips, L.S., Sarto, G.E. Psychiatric disorders and cognitive dysfunction among older,
postmenopausal women: Results from the Women’s Health Initiative-Memory Study. Am J Geriat Psych
18: 177-186, 2010.
Lin, E., Davis, S.S., Srinivasan, J., Sweeney, J.F., Ziegler, T.R., Phillips, L.S., Gletsu-Miller, N. Dual
mechanism for type 2 diabetes resolution after Roux-en-Y gastric bypass. Amer Surgeon 75: 498-502,
2009.
Shikany J.M., Tinker, L.F., Neuhouser, M.L., Ma, Y., Patterson, R.E., Phillips, L.S., Liu, S., Redden,
D.T. Association of glycemic load with cardiovascular disease risk factors: The Women's Health
Initiative Observational Study. Nutrition 26: 641-647, 2010.
Olson, D.E., Rhee, M.K., Herrick, K., Ziemer, D.C., Twombly, J.G., Phillips, L.S. Screening for diabetes
and prediabetes with proposed A1c-based diagnostic criteria. Diab Care 33: 2184-2189, 2010.
Allison, M.A., Manson, J.E., Aragaki, A., Langer, R.D., Rossouw, J., Curb, D., Martin, L.W., Phillips.
L.S., Stefanick, M.L., Cochrane, B.B., Sarto, G., Barnhart, J., O'Sullivan, M.J., Johnson, K.C., Gass, M.,
Trevisan, M., Woods, N.F. Vasomotor symptoms and coronary artery calcium in postmenopausal
women. Menopause. 17: 1136-1145, 2010.
Lin, E., Liang, Z., Davis, S.S., Jr., Sweeney, J.F., Ziegler, T.R., Phillips, L.S., Gletsu-Miller, N.
Improvement in beta-cell function in patients with normal- and hyper-glycemia following roux-en-y
gastric bypass surgery. Amer J Physiol 299: E706-E712, 2010.
Bergenstal, R.M., Wysham, C., MacConell, L., Malloy, J., Walsh, B., Yan, P., Wilhelm, K., Malone, J.,
Porter, L.E., DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus
sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a
randomised trial. Lancet 376: 431-439, 2010.
Manson, J.E., Allison, M.A., Carr, J.J., Langer, R.D., Cochrane, B.B., Hendrix, S.L., Hsia, J., Hunt, J.R.,
Lewis, C.E., Margolis, K.L., Robinson, J.G., Rodabough, R.J., Thomas, A.M.; Women's Health Initiative
and Women's Health Initiative-Coronary Artery Calcium Study Investigators. Calcium/vitamin D
supplementation and coronary artery calcification in the Women's Health Initiative. Menopause 17: 683691, 2010.
Chao, C., Song, Y., Cook, N., Tseng, C.H., Manson, J.E., Eaton, C., Margolis, K.L., Rodriguez, B.,
Phillips, L.S., Tinker, L.F., Liu, S. The lack of utility of circulating biomarkers of inflammation and
endothelial dysfunction for Type 2 diabetes risk prediction among postmenopausal women: The Women's
Health Initiative Observational Study. Arch Intern Med 170: 1557-6520, 2010.
Twombly, J.G., Long, Q., Zhu, M., Fraser, L.-A., Olson, D.E., Wilson, P.W.F., Narayan, K.M.V.,
Phillips, L.S. Validity of the primary care diagnosis of diabetes in veterans in the southeastern United
States. Diab Res Clin Pract 91: 395-400, 2011.
Olson, D.E., Rhee, M.K., Herrick, K., Ziemer, D.C., Twombly, J.G., Phillips, L.S. Screening for diabetes
and prediabetes with proposed A1c-based diagnostic criteria: Response to Buse. Diab Care 33 (12):
e175, 2010 (doi: 10.2337/dc10-1823).
Driscoll, I., Espeland, M.A., Wassertheil-Smoller, S., Gaussoin, S.A., Ding, J., Granek, I.A., Ockene,
J.K., Phillips, L.S., Yaffe, K., Resnick, S.M. Weight change and cognitive function: Findings from the
Women’s Health Initiative study of cognitive aging. Obesity 19: 1595-1600, 2011.
Robinson, J.G., Manson, J.E., Larson, J., Liu, S., Song, Y., Howard, B.V., Phillips, L.S., Shikany, J.M.,
Allison, M., Curb, J.D., Johnson, K.C., Watts, N.B. Lack of association between 25(OH)D levels and
incident type 2 diabetes in older women. Diabetes Care 34: 628-634, 2011.
Shikany, J.M., Margolis, K.L., Pettinger, M., Jackson, R.D., Limacher, M.C., Liu, S., Phillips, L.S.,
Tinker, L.F. Effects of a low-fat dietary intervention on glucose, insulin, and insulin resistance in the
Women’s Health Initiative Dietary Modification trial. Amer J Clin Nutr 94(1): 75-85, 2011.
Allison, M.A., Manson, J.E., Aragaki, A., Eaton, C.B., Hsai, J., Phillips, L.S., Kuller, L., Trevisan, M.
Resting heart rate and coronary artery calcium in postmenopausal women. J Womens Health 20: 661-669,
2011.
Chacko, S.A., Song, Y., Manson, J.E., Van Horn, L., Eaton, C., Martin, L.W., McTiernan, A., Curb, J.D.,
Wylie-Rosett, J., Phillips, L.S., Plodkowski, R.A., Liu, S. Allison, M.A., Manson, J.E., Aragaki, A.,
23
Document1
195.
196.
197.
198.
199.
200.
201.
202.
203.
204.
205.
206.
207.
Eaton, C.B., Hsai, J., Phillips, L.S., Kuller, L., Trevisan, M. Serum 25-hydroxyvitamin D concentrations
in relation to cardiometabolic risk factors and metabolic syndrome in postmenopausal women. Am J Clin
Nutr 94(1): 209-17, 2011.
LaCroix, A.Z., Chlebowski, R.T., Manson, J.E., Aragaki, A.K., Johnson, K.C., Martin, L., Margolis,
K.L., Stefanick, M.L., Brzyski, R., Curb, J.D., Howard, B.V., Lewis, C.E., Wactawski-Wende, J.; WHI
Investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal
women with prior hysterectomy: a randomized controlled trial. JAMA 305(13):1305-14, 2011.
Michael, Y.L., Smit, E., Seguin, R., Curb, J.D., Phillips, L.S., Manson, J.E.. Serum hydroxyvitamin D and
physical performance in postmenopausal women. J Womens Health 20: 1603-1608, 2011.
Shah, R.U., Winkleby, M.A., Van Horn, L., Phillips, L.S., Eaton, C.B., Martin, L.W., Rosal, M.C.,
Manson, J.E., Ning, H., Lloyd-Jones, D.M., Klein, L. Education, income, and incident heart failure in
post-menopausal women. The Women's Health Initiative Hormone Therapy Trials. J Am Coll Cardiol.
58(14):1457-64, 2011.
Margolis, K.L., Wei, F., de Boer, I.H., Howard, B.V., Liu, S., Manson, J.E., Mossavar-Rahmani, Y.,
Phillips, L.S., Shikany, J.M., Tinker, L.F.; for the Women’s Health Initiative Investigators. A diet high in
low-fat dairy products lowers diabetes risk in postmenopausal women. J Nutr. 141: 1969-1974, 2011.
Tinker, L.F., Sarto, G.E., Howard, B.V., Huang, Y., Neuhouser, M.L., Mossavar-Rahmani, Y., Beasley,
J.M., Margolis, K.L., Eaton, C.B., Phillips, L.S., Prentice, R.L. Biomarker-calibrated dietary energy and
protein intake associations with diabetes risk among postmenopausal women from the Women's Health
Initiative. Am J Clin Nutr. 94: 1600-1606, 2011.
Chlebowski,R.T., McTierman, A., Wactawski-Wende, J., Manson, J.E., Aragaki, A., Rohan, T., Ipp, E.,
Kaklamani, V.G., Vitolins, M., Wallace, R., Gunter, M., Phillips, L.S., Strickler, H., Margolis, K., Euhus,
D.M. Diabetes, metformin and breast cancer in postmenopausal women. J Clin Oncol 30: 2844-2852,
2012.
Ma, Y., Hebert, J.R., Manson, J.E., Balasubramanian, R., Liu, S., Lamonte, M., Bird., C.E., Ockene, J.K.,
Qiao, Y., Olendzki, B., Schneider, K.L., Rosal, M.C., Sepavich, D.M., Wactawski-Wende, J., Stefanick,
M., Phillips, L.S., Ockene, I.S., Kaplan, R.C., Sarto, G.E., Garcia, L., Howard, B.V. Determinants of
racial/ethnic disparities in incidence of diabetes in postmenopausal women in the United States: the
Women’s Health Initiative 1993- 2009. Diab Care 35: 2226-2234, 2012.
You, N.C., Chen, B.H., Song, Y., Lu, X., Chen, Y., Manson, J.E., Kang, M., Howard, B.V., Margolis,
K.L., Curb, J.D., Phillips, L.S., Stefanick, M.L., Tinker, L.F., Liu, S. A prospective study of leukocyte
telomere length and risk of type 2 diabetes in postmenopausal women. Diabetes 61: 2998-3004, 2012.
Elena, J.W., Steplowski, E., Yu, K., Hartge, P., Tobias, G.S., Brotzman, M.J., Chanock, S.J., StolzenbergSolomon, R.Z., Arslan, A.A., Bueno-de-Mesquita, H.B., Helzlsouer, K., Jacobs, E.J., Lacroix, A.,
Petersen, G., Zheng, W., Albanes, D., Allen, N.E., Amundadottir, L., Bao, Y., Boeing, H., BoutronRuault, M.C., Buring, J.E., Gaziano, J.M., Giovannucci, E.L., Duell, E.J., Hallmans, G., Howard, B.V.,
Hunter, D.J., Hutchinson, A., Jacobs, K.B., Kooperberg, C., Kraft. P., Mendelsohn, J.B., Michaud, D.S.,
Palli, D., Phillips, L.S., Overvad, K., Patel, A.V., Sansbury, L., Shu, X.O., Simon, M.S., Slimani, N.,
Trichopoulos, D., Visvanathan, K., Virtamo, J., Wolpin, B.M., Zeleniuch-Jacquotte, A., Fuchs, C.S.,
Hoover, R.N., Gross, M. Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic
cancer cohort consortium. Cancer Causes Control 24: 13-25, 2012.
Chatterjee, R., Narayan, V.K.M., Lipscomb, J., Jackson, S.L., Long, Q., Zhu, M., Phillips, L.S. Screening
for diabetes and prediabetes should be cost-saving in high-risk patients. Diab Care 36: 1981-1987, 2013.
Gletsu-Miller, N., Kahn, H.S., Gasevic, D., Liang, Z., Frediani, J.K., Torres, W.E., Ziegler, T.R., Phillips,
L.S., Lin, E. Sagittal abdominal diameter and visceral adiposity: Correlates of beta-cell function and
dysglycemia in severely obese women. Obesity Surgery 23: 874-881, 2013..
Staimez, L.R., Weber, M.B., Ranjani, H., Ali, M.K., Echouffo-Tcheugui, J.B., Phillips, L.S., Mohan, V.,
Narayan, K.M.V. Evidence of reduced beta cell function in Asian Indians with mild dysglycemia. Diab
Care 36: 2772-2778, 2013.
Ma, Y., Hebert, J., Balasubramanian, R., Pagoto, S., Schneider, K., Phillips, L.S., Goveas, J., Anniel, C.,
Olendzki, B., Beck, J., Smoller, J.S., Sepavich, D.M., Ockene, J., Uebelacker, L., Zorn, M., Liu, S.
Relations of depressive symptoms and antidepressant use to body mass index and selected biomarkers for
diabetes and cardiovascular disease. Am J Public Health 103: e34-e43, 2013.
24
Document1
208.
209.
210.
211.
212.
213.
214.
215.
216.
Wolpin, B.M., Bao, Y., Qian, Z.R., Kraft, P., Ogino, S., Stampfer, M.J., Sato, K., Ma, J., Buring, J.E.,
Sesso, H.D., Lee, I.M., Gaziano, J.M., McTiernan, A., Phillips, L.S., Cochrane, B.B., Pollak, M.N.,
Manson, J.E., Giovannucci, E.L., Fuchs, C.S. Hyperglycemia, Insulin Resistance, Impaired Pancreatic βCell Function, and Risk of Pancreatic Cancer. J Natl Cancer Inst 105: 1027-1035, 2013.
Ma Y, Hébert JR, Balasubramanian R, Wedick NM, Howard BV, Rosal MC, Liu S, Bird CE, Olendzki
BC, Ockene JK, Wactawski-Wende J, Phillips LS, Lamonte MJ, Schneider KL, Garcia L, Ockene IS,
Merriam PA, Sepavich DM, Mackey RH, Johnson KC, Manson JE. All-Cause, Cardiovascular, and
Cancer Mortality Rates in Postmenopausal White, Black, Hispanic, and Asian Women With and Without
Diabetes in the United States: The Women's Health Initiative, 1993-2009. Am J Epidemiol. 178: 15331541, 2013.
Shufelt CL, Merz CN, Prentice RL, Pettinger MB, Rossouw JE, Aroda VR, Kaunitz AM,
Lakshminarayan K, Martin LW, Phillips LS, Manson JE. Hormone therapy dose, formulation, route of
delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative
Observational Study. Menopause. Menopause. 2014 Mar;21(3):260-6.
Rodbard HW, Cariou B, Zinman B, Handelsman Y, Philis-Tsimikas A, Skjøth TV, Rana A, Mathieu C;
BEGIN Once Long trial investigators. Comparison of insulin degludec with insulin glargine in insulinnaive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med. 2013
Nov;30(11):1298-304.
Dubowitz N, Xue W, Long Q, Ownby JG, Olson DE, Barb D, Rhee MK, Mohan AV, Watson-Williams
PI, Jackson SL, Tomolo AM, Johnson TM II, Phillips LS. Aging is associated with increased A1c
independent of glucose levels and insulin resistance, and decreased diagnostic specificity. Diabet Med.
2014 Aug; 31(8):927-35.
Zambrana RE, López L, Dinwiddie GY, Ray RM, Phillips LS, Trevisan M, Wassertheil-Smoller S.
Prevalence and Incident Prehypertension and Hypertension in Postmenopausal Hispanic Women: Results
from the Women's Health Initiative. Am J Hypertens. 2014 Mar; 27(3):372-81.
Musselman DL, Ziemer DC, McNutt MD, Seay JS, Royster EB, Larsen B, Barham T, Brown AR, Vogel
OL, Phillips LS, Harvey PD. Depression, deficits in functional capacity, and impaired glycemic control
in urban African Americans with type 2 diabetes. J Psychiatr Res. 2014 May; 52:21-7.
Rapp SR, Espeland MA, Manson JE, Resnick SM, Bryan NR, Smoller S, Coker LH, Phillips LS,
Stefanick ML, Sarto GE; Women's Health Initiative Memory Study. Educational attainment, MRI
changes, and cognitive function in older postmenopausal women from the Women's Health Initiative
Memory Study. Int Psychiatry Med. 2013;46(2):121-43.
Merjaneh L, He Q, Long Q, Phillips LS, Stecenko AA. Disposition index identifies defective beta-cell
function in cystic fibrosis subjects with normal glucose tolerance. J Cyst Fibros. 2014 Jul 3. pii: S15691993(14)00153-2. doi: 10.1016/j.jcf.2014.06.004. [Epub ahead of print]
25
Document1
BOOK CHAPTERS, REVIEW ARTICLES, AND EDITORIALS
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
Phillips, L.S., Herington, A.C., and Daughaday, W.H.: Hormone effects on somatomedin action and
somatomedin generation. Advances in Human Growth Hormone Research (Proceedings of a
Symposium), DHEW Publication 74-612, 1974, pp. 50-75.
Phillips, L.S.: Diabetes Mellitus. In: Manual of Medical Therapeutics, 21st edition. Little, Brown, and
Co., Boston, 1974, pp. 345-361.
Daughaday, W.H., Phillips, L.S., and Herington, A.C.: Measurement of somatomedin by cartilage in
vitro. Meth of Enzymol 37B:93-109, 1975.
Daughaday, W.H., Herington, A.C., and Phillips, L.S.: The control of growth by endocrines. Ann Rev
Physiol 37:211-244, 1975.
Daughaday, W.H., Phillips, L.S., and Herington, A.C.: Somatomedin generation by perfused livers. Adv
Metab Dis 8:151-157, 1975.
Daughaday, W.H., Phillips, L.S., and Herington, A.C.: Regulation of somatomedin generation. In:
Growth Hormone and Related Peptides. Proceedings of the Third International Symposium, Excerpta
Medica, Amsterdam, 1976, pp. 169-177.
Phillips, L.S., and Daughaday, W.H.: Bioassay of somatomedin. Proceedings of the Vth International
Congress of Endocrinology, Excerpta Medica, International Congress Series #403, V.H.T. James, ed.,
Amsterdam, 1977, Vol. 2, pp. 150-161.
Phillips, L.S.: Nutritional Regulation of Somatomedin and Growth. In: Somatomedins and Growth,
Proc. Serono Symposia, v. 23, Giordano, G., Van Wyk, J.J., and Minuto, F., eds., Academic Press, New
York, 1979 pp. 311-323.
Phillips, L.S., and Vassilopoulou-Sellin, R.: Nutritional regulation of somatomedin. Amer J. Clin Nutr
32:1082-1096, 1979.
Phillips, L.S., Belosky, D.C., Reichard, L.A., Young, H.S., Berkowitz, S.R., and Pertcheck, M.F.:
Somatomedin(s) and somatomedin inhibitors(s) in normal and diabetic serum. In: Somatomedins and
Growth, Proc. Serono Symposia, v. 23; Giordano, G., Van Wyck, J.J., and Minuto, R., eds., Academic
Press, New York, 1979, pp. 209-212.
Phillips, L.S., and Vassilopoulou-Sellin, R.: Somatomedins. N Engl J Med 302:371-380 and 438-446,
1980.
Phillips, L.S.: Nutrition, metabolism, and growth. In: Endocrine Control of Growth. Daughaday, W.H.,
Ed., Elsevier North-Holland, New York, 109-161, 1981.
Phillips, L.S.: Nutrition and somatomedins. In: Nutritional Assessment: Present Status, Future
Directions and Prospects, Report of the Second Ross Conference in Medical Research. Levenson, S.M.,
ed., Ross Laboratories, Columbus, pp. 51-56, 1981.
Freinkel, N., Metzger, B.E., Cockroft, D., Phelps, R.L., Lewis, N.J., Gorman, L., Ogata, E.S., Boehm,
J.J., Depp, R., Dooley, S., Shambaugh III, G.E., Bauman, G., LaBarbera, A., Phillips, L.S., and Vaisrub,
N.: Inquiries into maternal metabolism: Past, present and future -- a progress report from the
Northwestern University Diabetes in Pregnancy Center. In: Diabetes 1982, E.N. Mngola, ed, Int Cong
Feder No. 600, Excerpta Medica, Amsterdam, 1983, pp. 423-427.
Phillips, L.S.: Nutrition, insulin and somatomedins. In: Growth Retardation among Children and
Adolescents with Inflammatory Bowel Disease, (M. Davidson, ed.) National Foundation for Ileitis and
Colitis, Inc. New York, 1983, pp. 179-211.
Phillips, L.S., and Unterman, T.G.: Somatomedin activity in disorders of nutrition and metabolism. Clin
Endocrinol Metab 13:145-189, 1984.
Phillips, L.S., Unterman, T.G.: Increased somatomedin inhibitors in renal failure. In: Human Growth
Hormone; Raiti, S., and Tolman, R.A., eds, Plenum, New York, 1986, pp. 575-584.
Phillips, L.S.: Endocrinology and Metabolism Section, Textbook Subeditor, "Medicine for the Practicing
Physician", 2nd. ed. Hurst J.W., ed., Butterworth, Inc., Boston, MA, pp. 430-574, 1988.
Phillips, L.S.: Somatomedin Inhibitors. In: Disorders of Human Growth: Advances in Research and
Treatment. Grave, G.D., Cassorla, F.G., eds., Charles C. Thomas, Springfield, IL, pp. 96-115, 1989.
Phillips, L.S., Goldstein, S., Klein, J.D.: Somatomedin Inhibitors. In: Molecular and Cellular Aspects of
IGF-1. LeRoith, D. and Raizada, M.K., eds. Plenum Publishing Company., pp. 81-95, 1989.
26
Document1
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
Phillips, L.S., Harp, J.B., Goldstein, S., Klein, J., Pao, C-I.: Regulation and action of insulin-like growth
factors at the cellular level. Proc Nutr Soc 49: 451-458, 1990.
Phillips, L.S. and Robertson, D.G.: Insulin-like growth factors and non-islet cell tumor hypoglycemia.
Metabolism 42: 1093-1101, 1993.
Krishna, A.Y. and Phillips, L.S.: Fetal alcohol syndrome and insulin-like growth factors. J Lab Clin Med
124: 149-151, 1994.
Krishna, A.Y. and Phillips, L.S.: Management of acromegaly. Amer J Med Sci 308: 370-375, 1994.
Krishna, A.K. and Phillips, L.S. Growth hormone - IGF-I axis. In: Growth Factors and Wound Healing:
Basic Science and Potential Clinical Applications; Ziegler, T.R., Pierce, G.F., and Herndon, D.N., eds.,
Serono, Norwell, MA , pp. 56-76, 1997.
Phillips, L.S., Pao, C.-I, and Villafuerte, B.C.: Molecular regulation of insulin-like growth factor-I (IGFI) and its principal binding protein, IGFBP-3. In: Progress in Nucleic Acid Research and Molecular
Biology; Moldave, K. and Cohn, W., eds., Academic Press, San Diego, CA, pp. 195-265, 1998.
Phillips, L.S. and Underwood, L. (eds.) The diagnosis and management of adult growth hormone
deficiency. Endocrinologist 8 (Suppl 1): 1S-40S, 1998.
Phillips, L.S. and Kaytor, E.N. Metabolic regulation of IGF-I gene expression. Journal of Animal
Science 77 (Suppl 33): 43-54, 1999.
Phillips, L.S., Miller, C.D. Diabetes Mellitus. In: EBM Solutions Guidelines for Health Care Providers
and Consumers [online database]. Issue 1. Nashville, Tenn: EBM Solutions; 2000.
Phillips, L.S., Dunning, B.E. Starlix (nateglinide): update on a new antidiabetic agent. Int J Clin Pract
57(6): 535-41, 2003.
Musselman, D.L., Betan, E., Larson, H.H., Phillips, L.S. The relationship of depression to diabetes - Type
1 and Type 2: Epidemiology, biology, and treatment. Biological Psychiatry 54: 317-329, 2003.
Phillips, L.S. Diabetes: update on management and treatment. Ethn. Dis. 13 (Suppl 3): S32-3, 2003.
Phillips, L.S., Langer, R.D. Postmenopausal hormone therapy: Critical reappraisal and a unified
hypothesis. Fert Stert 83: 558-566, 2005.
Phillips, L.S., Rhee, M.K. The metabolic syndrome and glucose intolerance. Hospital Physician 42: 2638, 2006.
Musselman, D.L., Bowling, A., Gilles, N., Larsen, H., Betan, E., Phillips, L.S. The interrelationship of
depression and diabetes. In: Depression and Physical Illness; Steptoe, A. ed., Cambridge, New York,
N.Y., pp. 165-194, 2007.
Phillips, L.S., Twombly, J.G. It’s time to overcome clinical inertia. Ann Int Med 148: 783-785, 2008.
Weber, M.B., Twombly, J.G., Narayan, K.G.M., Phillips, L.S. Lifestyle interventions and the prevention
and treatment of type 2 diabetes. Am J Lifestyle Med 4: 468-480, 2010.
Mohan, A.V., Phillips, L.S. Clinical inertia and uncertainty in medicine. JAMA 306: 383, 2011.
Phillips, L.S., Olson, D.E. Diabetes: Normal glucose levels should be the goal. Nat Rev Endo 8: 510512, 2012.
Weber MB, Twombly JG, Narayan KMV, Phillips LS. Diabetes Mellitus and Lifestyle. In: Rippe JM, ed.
Encyclopedia of Lifestyle Medicine & Health. Thousand Oaks, California: Sage Publication; 2012:32334.
Weber MB, Staimez L, Gilligan J, Narayan KMV, Phillips LS. Lifestyle Medicine and the Treatment of
Glucose Intolerance. In: Rippe JM, ed. Textbook of Lifestyle Medicine. Second ed: CRC Press; 2013.In
Press.
27